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Abstract 
 The sustainable manufacturing of medicines, materials and chemicals is 
enabled with biotechnology, and the key to the development of new processes, as well 
as improvement of existing ones, lies in our fundamental understanding of the 
biological systems we manipulate. Recombinant protein production is at the core of 
biotechnology and numerous molecular tools and bacterial strains have been 
developed over the past four decades for this purpose. Understanding of the genetic 
code and our ability to manipulate genetic material, paves the way for the microbial 
cell factory development that enables production of protein in a sustainable, cost-
efficient manner. In this thesis I report the joined efforts of my colleagues and myself, 
to improve the premises for cell factory development by optimizing the cloning 
strategies, improving the awareness of unforeseen side-effects in complex bacterial 
expression systems, and building a platform for enhanced expression of certain plant 
genes in bacteria. The relevance of the conducted research to the field of 
biotechnology is covered, as well as necessary scientific background and history. 
Specifically, the surprisingly minor effects of tRNA overexpression on the production 
of a large number of membrane proteins in Escherichia coli are reported, and also the 
subsequent work elucidating two types of side effects: in some cases growth and gene 
expression are directly impaired by the extra tRNA sequences and in other cases the 
apparent positive effects are instead caused by a differential expression of the 
lysozyme gene encoded on the same plasmid. These phenomena seem to have been 
largely overlooked despite the huge popularity of the T7/pet-based systems for 
bacterial protein production. Additionally, the paradox that standardization comes at 
the cost of reduced flexibility is addressed. The development of a cloning strategy is 
covered, aiming at maximized standardization while maintaining high flexibility in 
choice of cloning technique. Finally, the systematic optimization of production of six 
plant-derived cytochrome P450 enzymes in E. coli, using a high-throughput workflow 
based on C-terminal fusions to the green fluorescent protein is also presented.  Our 
work suggests that there are no inherent limitations in using different standard E. coli 
strains and expression conditions for exploiting cytochrome P450s for 
biotechnological applications. The results of this thesis have improved the premises 
for cell factory development in the future. 
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Dansk resumé 
 Den grundlæggende forståelse af biologiske systemer bærer nøglen til en 
bæredygtig produktion af medicin, kemikalier og materialer, og bioteknologien 
muliggør dette. Produktion af rekombinante proteiner er helt centralt for den 
bioteknologiske industri. Talrige molekylære værktøjer og mikroorganismer er blevet 
udviklet  gennem de seneste fire årtier, for at udvikle nye processer og forbedre 
eksisterende, med henblik på netop rekombinant proteinproduktion. Vejen til at 
udvikle mikrobielle cellefabrikker går gennem en forståelse af den genetiske kode og 
vores evne til at manipulere arvemasse: Dette gør os i stand til at skabe bæredygtige 
og omkostningseffektive systemer. I denne afhandling præsenteres mine kollegers og 
min fælles indsats for at forbedre præmisserne for udviklingen af cellefabrikker 
gennem i) øget opmærksomhed på uforudsete effekter i komplekse bakterielle 
produktionssystemer ii) optimering af kloningsstrategier og iii) udviklingen af en 
platform til ekspression af en bestemt klasse af plantegener i bakterier. Der redegøres 
for forskningens relevans for bioteknologi, suppleres med nødvendig 
baggrundsinformation og et historisk perspektiv. Konkret vises det at øget ekspression 
af tRNA-gener, der afkoder sjældent forekommende kodons har overraskende lille 
effekt på membranproteiner i Escherichia coli, og efterfølgende belyses to typer af 
sideeffekter ved denne fremgangsmåde: I visse tilfælde er vækst og proteinproduktion 
nedsat som en direkte effekt af de ekstra tRNA-gener. I andre tilfælde ses det at den 
tilsyneladende positive effekt på proteinproduktion ikke skyldes tRNA-generne, men 
forskellige niveauer af enzymet T7 lysozym, som er udtrykt fra samme plasmid. Disse 
fænomener har været overset, på trods af den store popularitet som T7/pET-baserede 
systemer til proteinproduktion i bakterier har fået. Ydermere addresseres det 
paradoks, at standardisering af kloning oftest betyder reduceret fleksibilitet. 
Udviklingen af en kloningsstrategi sigtet mod maksimal standardisering, hvor 
fleksibiliteten bevares rapporteres. Endelig gennemgås den systematiske optimering 
af en bakteriel produktionsplatform. Produktionen af seks cytochrom P450 enzymer 
fra planter optimeres ved brugen af reporter-proteinet GFP (green fluorescent 
protein). Dette studie antyder, at der ikke er nogen begrænsning for valg af Eschericia 
coli stammer til produktion af denne type enzymer. Sammenlagt har resultaterne af 
denne afhandling forbedret præmisserne for udviklingen af cellefabrikker fremover. 
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1.1 Introduction and synopsis 
 The capacity to endure. That is the definition of sustainability. In 
biosustainability the term is interpreted as the potential of maintaining or increasing 
the quality of life on earth, without depriving the planet of its resources. The 
accomplishment of this has become a heated subject of public debate. The world’s 
leaders meet to determine long-term climate goals to preserve our planet for future 
generations, and The United Nations have increased its focus on sustainability. By 
September 2015, the Sustainability Development Goals1 were a reality. The 17 goals 
have a broad focus with ambitious targets, covering poverty and equality goals, and 
climate goals to preserve the planet. Researchers in academia and industry are 
developing sustainable solutions to replace exhaustible resources by renewable 
supplies. A widespread production of medicine, chemicals and materials from 
sustainable sources mark the accomplishments of this industry2,3, and show a future 
where biotechnology offers some of the solutions to reach a sustainable development.  
Synopsis 
 In the constant chase for better, cheaper or easier ways of producing proteins, 
the multitude of available systems is a major benefit, but the vast amount of options 
can turn into a downside. There are many ways to reach an optimal solution, and the 
scientific work described in chapters 2-4 reveals some of the facets of working with 
microbial cell factory development. A curiosity about an expression system 
encompassing overexpression of tRNAs, developed to provide universal expression of 
eukaryotic genes in E. coli, founded the work described in chapter 2. We tested the 
system in a high-throughput manner, and subsequently in small scale, to discover 
surprising effects of the system, which are important for heterologous gene 
expression. A desire for a standardized cloning platform without the drawbacks of 
such already existing technologies fueled the work described in chapter 3, where we 
successfully obtain state-of-the art levels of our test compound protoporphyrin IX, in 
two simple design-build-test cycles. Finally, the need for better expression of 
membrane bound protein genes, particularly plant derived cytochrome P450s, paved 
the way for our development of an optimal production platform. The work is 
described in chapter 4, and this contribution thus adds this plant multi-membered key 
enzyme family to the toolbox for bacterial cell factory design.  
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1.2 History of biotechnology in brief 
 Since ancient times biotechnology has been used by humans to manipulate 
biological systems. The production of beer, bread and cheese dates back to the 
beginning of documented history. Plants and animals have been domesticated and 
manipulated without ever cloning a gene in the laboratory. The emergence of classical 
molecular biology traces back 60 years, when James Watson, Francis Crick and 
Rosalin Franklin elucidated the molecular structure of nucleic acids4. Recombinant 
DNA techniques were developed in the early 1970s5–8, and by 1981 the first major 
products hit the market9. Today, the industry is a 300 billion dollar market, with 
growth rates around ten percent through the past five years10. Production of 
recombinant proteins has opened a new era, and proteins that were previously difficult 
to produce are now easily obtained in cell factories developed for the purpose11.  
 
1.3  Cell factories 
 Life is built on the same basic principles, regardless of life form, and this is 
the key that made it possible to develop cell factories. The term reveals the concept: a 
cell factory is a cell manipulated to work like a factory. Depending on the 
manipulations, the factory can produce chemicals, proteins, enzymes, or maybe the 
cell itself is the product. The demand for cell factories and technologies that allow for 
their manipulation is increasing. These technologies are developing at a fast pace and 
the performance of cell factories is promising for future applications. The choice of a 
cell factory takes into account several factors with robustness, available engineering 
tools, and survival under desired process conditions at the top of the list. The Gram-
negative bacterium Escherichia coli is comprehensively investigated and widely used 
in industry12.  
 The first commercial enzyme was used as a detergent, and reached the market 
in 191413. When microbial proteases were introduced in washing powders in 1959, 
the real breakthrough for industrial enzymes took place. In 1965, the major detergent 
companies started using the first commercial protease from Bacillus sp.14 which was 
produced the Danish company Novo (now Novozymes). This was the start for the big 
business of enzymes for the world known company.  
Chapter 1 
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 The full establishment of the cell factory concept happened when the first 
recombinant pharmaceutical reached the market in the early 80's. The product was 
human insulin, and this was produced in E. coli cell15. The Food and Drug 
Administration (FDA) and European Medicines Agency (EMEA) have licensed more 
than 150 protein-based recombinant pharmaceuticals. Out of these almost one third 
are obtained in E. coli. The engineering of strains has allowed for a progressive 
development of new cell factories with enhanced performance. Early cell factories 
were a product of untargeted mutagenic strategies and phenotypic selection, but 
directed genetic and metabolic engineering soon became important players as well16. 
In parallel with a strong focus on the well-studied unicellular organisms such as E. 
coli and S. cerevisiae as cell factories, high quality proteins have been produced in 
mammalian cells and insects, where the multicellular complexity can be a strong 
advantage, as they can perform posttranslational modification which can otherwise be 
the limiting factor. Microbial species with unusual traits have gained focus as well, 
including algae, fungi, and moss16.  
 Whether aiming at producing a protein, enzyme or chemical, there are several 
factors to consider. The process of developing a cell factory is often initiated by the 
choice of host. There are a wide range of hosts to consider, depending on desired 
traits17. With the choice of host, the technology available for the project is defined by 
the availability of molecular tools, equipment and previous research18. For products 
requiring post-translational modifications, a eukaryote host can be preferable19, but 
often, bacterial hosts are preferred due to their relatively small size, rapid 
reproduction, and metabolic diversity. Here, a minor selection of bacterial cell 
factories is covered, and further review of bacterial cell factories is covered by 
Demain et al17, Rosano et al18, Ferrer-Miralles et al20, Westers et al21 and Morello et 
al22 where as eukaryotic cell factories are reviewed by Demain et al17 and Punt et al23.  
 Recombinant protein production is among others carried out in the Gram 
positive strains Bacillus subtilis and Lactococcus lactis, from which secretion of 
proteins of interest into the medium is easily obtained, due to their secretory 
pathways22. This enables easier downstream processing, as the product can be purified 
directly from the medium20. Endotoxins can be a problem with some bacterial hosts, 
when producing therapeutics for use in humans, as they are known to induce fever24. 
B. subtilis is free of endotoxins, and this feature is convenient for therapeutics 
Chapter 1 
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production, since it eliminates the need for downstream endotoxin removal22. Both B. 
subtilis and L. lactis are well studied organisms, and their genomes have been 
sequenced25,26. Additionally, genetic tools are available, and the behavior under 
different growth conditions is well documented, making the link from laboratory 
development to industrial production shorter27–30,31.  
 Some of the challenges in heterologous gene expression require special traits 
in a production host. Rather than attempting to overcome these with a traditional host 
of choice, alternative sources can be considered. For example Pseudomonas putida 
which has extraordinary metabolical versatility genus with a diverse biotechnological 
potential, as it is highly tolerant to solvents and high temperature32. This enables the 
production of several bulk and fine chemicals in high titers33.  P. putida is a new 
player in the field of microbial cell factories, and some of the limitations are caused 
by the early progress-stage, where lack of knowledge in genotype/phenotype 
relationships poses a constraint in the applications32.   
 E. coli is a popular choice for recombinant protein production and expression 
of pathways. Additionally, it is widely used for cloning, genetic modifications, and 
small-scale production for research purposes. Historically, the bacterium has been 
widely studied and the development of molecular genetics has mainly been based on 
E. coli34. Likewise, it was the first organism to get FDA-approval recombinant protein 
production20. Since the organism is well established in each laboratory, it often 
becomes the first choice of expression host. The advantages of using E. coli includes 
the fast doubling time (20 minutes under optimal conditions35), easily obtainable high 
cell densities36, and easy transformation with exogenous DNA as well as plasmid 
purification37.  
 Many of the challenges encountered when producing a recombinant protein in 
E. coli are general to cell factories, but often context dependent. For example, product 
toxicity can have fatal consequences for the host. This issue can be resolved by 
controlling the expression with a different, tighter promoter system, a weaker 
promoter, or lower induction concentration. Ultimately the solution can be a different 
choice of host. The formation of inclusion bodies, intracellular granules of protein38, 
poses a major bottleneck in recombinant protein production39. In inclusion bodies, the 
protein is inactive and cannot perform its task. When inclusion bodies are a persistent 
problem, several strategies exist to downstream processing of the proteins, to obtain a 
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fully functional product40. The therapeutic use of recombinant proteins from E. coli is 
also complicated by the accumulation of endotoxins as mentioned earlier. It requires 
an additional purification step to have a final endotoxin-free product24. Below follows 
a more detailed overview of the expression system often applied when expressing 
heterologous genes in E. coli, and section 1.4 contains an elaboration on E. coli cell 
factories.  
 
1.4 The E. coli strain BL21: "the gold standard" 
  Despite the worldwide use of E. coli for experimental biology, the 
majority of E. coli laboratory strains descend from a few individual isolates41: K-12, 
often used for cloning, and the B-strains, often used for expression. K-12 has a 
straightforward history: It was isolated from a patient suffering from convalescent 
diphtheria in 192242.  The B-strain has a more complex origin, being shared and 
renamed between researchers for decades. The strain has been traced back to 1918, 
when it was used at the Pasteur Institute in Paris41. When fast-forwarding to the 
present, numerous derivatives of both strain types exist. Derivatives of K-12 such as 
DH5α and DH10b are often used for cloning, and they are especially suitable for this 
purpose due to their recombination and endonuclease deficiencies, and the possibility 
to perform blue/white screening (not covered here, but described in detail by H. 
Miller53 and S. T. Smale54). 
 
In E. coli laboratories one strain in particular has become the gold standard for 
recombinant protein expression: BL21(DE3). It has a genome integrated T7 RNAP, 
and together with vectors where T7 promoters controls the gene of interest, it 
comprises the T7 expression system45,46. This system was developed and patented45,46 
by William Studier and his colleagues45, and is described in detail in section 1.6. This 
innovation is still highly relevant as more papers are being published every year, as 
depicted in Figure 1. 
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Figure 1 Number of search hits pr. year for "BL21(DE3)" at pubmed.org 
 BL21 and derivative strains hereof are advantageous, as they are deficient in 
Lon and OmpT proteases. OmpT is known to degrade T7 RNAP, and lon mutants are 
known to exhibit decreased protein degradation47. Since the introduction of the strain 
in 1990 several derivative strains with traits specific for certain applications have 
been developed48. Several derivatives supply the genes for a number of minor tRNA 
species, to overcome a codon bias (covered in section 1.7), and one of the most 
remarkable variants is is the strain Rosetta2(DE3)pLysS (hereafter referred to as 
Rosetta).  
The work presented in chapter 2 of this thesis is focused on the applications and 
limitations within the Rosetta strain. Many of the additional variations of BL21 are 
reviewed by Kay Terpe48. The Rosetta contains the T7 expression system and a 
pRARE plasmid, which are both described in the following sections. The underlying 
assumptions for the design of this particular strain have its roots in the details of 
variability in the genetic code between species. Prior to a thorough review of the 
pRARE plasmid harbored by the Rosetta strain, the genetic principles are covered. 
 
1.5  Popular E. coli expression systems 
 In laboratories all over the world, E. coli is the preferred choice of host cell, 
and the positive consequence of this is a broad collection of tools for protein 
expression in E. coli. The most commonly used expression systems are listed in Table 
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1. Each system has certain key features making them suitable for different types of 
protein expression. 
Table 1 Popular E. coli expression systems and their key features. Adapted from K. Terpe48.  
Promoter Induction method Key features 
Plac49 IPTG Relative low-level 
expression; titratable, 
leaky 
Ptrc and Ptac50 IPTG High-level expression; 
titratable, leaky 
PT745 IPTG/rhamnose Very high-level 
expression, titratable, 
leaky 
Phage λ PR, PL51 Temperature shift High-level expression; 
tight control 
PtetA52 (Tetracycline) or 
anhydrotetracycline 
Mid- to high-level 
expression; tight 
ParaBAD53 L-arabinose Low- to high-level 
expression; titratable; tight 
Prha54 L-rhamnose Low- to high-level 
expression; titratable; tight 
 
 The expression systems Plac49, Ptrc50 and Ptac50 are all induced with the lactose-
analog isopropyl β-D-1-thiogalactosepyranoside (IPTG). This compound is used for 
induction of PT7 45 as well, but this action can also be performed with rhamnose, 
depending on strain system. Two different inducers can activate the same system, as 
induction is not directly of the promoter. The T7 promoters are not recognized by E. 
coli's own RNA polymerase, and the system is thus dependent on its own phage-
derived T7 RNA polymerase (T7 RNAP)45. Induction activates transcription of the 
polymerase from a Prha or PlacUV5 promoter, subsequently allowing transcription from 
T7 promoters. IPTG is an expensive inducer, and because of this these systems are 
most applicable for production of high-value compounds. Due to the low intracellular 
levels of protein obtained with Plac, this promoter is especially suitable for membrane 
protein production, or production of gene products which are toxic to the cell49. All 
Chapter 1 
9 
three promoter-systems Plac, Ptrc and Ptac are regulated by catabolite repression, and 
the T7 expression system was developed to offer an expression system free from 
catabolite repression. The IPTG-induced T7 expression system is an important 
element of the experimental work described chapter 2 and 4, and is thus further 
portrayed in section 1.6.  
 The λ phage promoters PL and PR also exploit the specificity of the phage 
genes, but in a different manner. Here, the promoter is controlled by the cI-repressor. 
The system is neat in its functionality since below 29°C the repressor is inactive, 
leaving the promoter available for constitutive expression. From 29°C and above, 
expression is repressed and then released again above 42°C51.  
 The tetracycline inducible PtetA system is a popular choice for heterologous 
gene expression due to its tight nature. The system relies on the repressor TetR, which 
is not encoded by an E. coli gene. The repressor is supplied on a plasmid, so the 
system is independent of strain choice. The induction is performed with an antibiotic 
which is clearly problematic, however, the use of anhydrotetracycline rather than 
tetracyclin relieves growth interference problems, and gives 35-fold higher promoter 
binding with a 100-fold less active antibiotic55.  
 The sugar-induced promoters ParaBAD and Prha are useful alternatives when a 
tight and titratable system is required for protein expression. The AraC activator 
controls expression from ParaBAD, and a high level of arabinose in the growth medium 
yields high expression. In absence of arabinose, the expression is tightly shut down53. 
The mechanism for gene synthesis from Prha relies on induction performed with L-
rhamnose, which activates transcription of the genes rhaS and rhaR. These genes 
regulate the L-rhamnose catabolism by activation of the rhamnose uptake and 
metabolism54, which allows transcription from Prha.  
 Due to the low cost, high productivity and rapid use, bacterial systems and 
especially E. coli, remain the most attractive choice for recombinant protein 
production56. The rational choice of expression system can determine failure or 
success, and it is thus important to understand the characteristics of the desired 
product, to enable informed decision-making. 
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1.6 The T7 expression system 
 The E. coli T7 expression system is very popular among researchers due to the 
specificity and potential for high intracellular target protein production45. The system 
is based on an E. coli lysogen of DE3, a phage lambda derivative carrying the T7 "1" 
gene, which encodes T7 RNAP controlled by the lacUV5 promoter45. This promoter 
is a strong variant of the wild type lac promoter, and being insensitive to catabolite 
repression, it is only controlled by the lac repressor lacI, which binds to the lac 
operator57.  
 The T7 expression system is shown in Figure 2. Bacteriophage T7 RNAP is 
highly selective for its own promoters which do not occur naturally in E. coli58, and is 
additionally very efficient in initiating transcription, and the elongating rate is around 
5 times faster than for E. coli RNA polymerase58,59. The production of T7 RNAP 
requires induction, and once the T7 expression system is active, the target protein 
produced from T7 promoters can constitute more than 50% of total cell protein in a 
few hours45.  
An important addition to the system was soon developed, to prevent leaky expression 
of T7 RNAP: T7 lysozyme, known to inhibit T7 RNAP, expressed on a plasmid60. 
Accumulation of T7 lysozyme does not prevent growth of E. coli cells despite of the 
enzyme’s amidase activity. The lysozyme cannot penetrate the inner membrane, and 
is therefor prevented from reaching its substrate, the peptidoglycan layer of the outer 
membrane60. Several T7 lysozyme-expressing plasmids were developed 
simultaneously for different purposes. They all carry the cat gene for chloramphenicol 
resistance, and the Ptet recognized by E. coli RNA polymerase. Both plasmids pLysS 
and pLysE have a Φ3.8 promoter (PΦ3.8), which is recognized by T7 RNAP, 
downstream of the gene. 
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Figure 2 The lac repressor LacI binds to PlacUV5 and inhibits transcription of T7 RNAP. The repression is 
not tight, and leaky expressed T7 RNAP is prevented from transcribing GOI from PT7 by T7 lysS. T7 lysS is 
expressed from a plasmid, driven by T7 PΦ3.8. Induction is performed with IPTG, which binds the lac 
repressor and allows transcription of T7 RNAP. T7 lysS is heavily diluted by T7 RNAP, and T7 RNAP can 
subsequently transcribe GOI from PT7. 
 
This allows the T7 RNAP to transcribe around the plasmid, and produce small 
amounts of T7 lysozyme mRNA46,61,100. Additionally, the lysozyme gene is oriented 
differently on the two plasmids, so pLysE allows for production of T7 lysozyme from 
Ptet as well, whereas pLysS only allows lysozyme to be produced from PΦ3.8. Two 
other plasmid variants, variants, pLysL and pLysH have no PΦ3.8, and can only 
produce lysozyme from Ptet. An additional variant of the lysozyme, LysY62 exists, 
which lacks the amidase activity, and can thus not perform cell lysis. This has been 
used to develop the pLEMO21 expression system, where Prha allows for titration and 
controls expression of the T7 lysozyme gene63. In the work presented chapter 2, the 
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pLysS version of the T7 lysozyme plasmid is applied in combination with either 
BL21(DE3) or the tRNA-supplying Rosetta(DE3), and the following section will 
unravel the biological importance of tRNAs.  
  
1.7  Codon bias and related challenges in heterologous gene 
expression  
 Upon deciphering of the genetic code the degeneracy became apparent4. 
Between one and six different nucleotide codons can encode a single amino acid, 
which allows for synonymous codon choice. The role of synonymous codon choice 
have puzzled scientists ever since, and it was soon discovered that the frequency for 
using a certain codon varies between different organisms64, a phenomenon termed 
codon bias. This bias seems restricted to simpler organisms, and have been observed 
in a broad variety of these64,65. When transferring genetic material from one genome 
to another, this bias can be problematic as the host might not transcribe and/or 
translate the foreign genetic sequence in an optimal manner. Partly, this may be 
caused by a parallel low abundance of transfer-RNAs (tRNAs) cognate to codons that 
are low in frequency – these codons are commonly referred to as rare codons66,67. 
Rare codons are defined by being used at a frequency below 0.05 % in the genome, 
and being decoded by less abundant tRNAs68. These tRNAs are interchangebly 
referred to as rare or minor tRNA species. For E. coli, this definition yields the 
following rare codons: CGA, CGG, AGG, GGA, AGA and AUA.  
 Numerous studies have shown that synonymous codon mutations can have 
drastic consequences for gene expression. Factors such as mRNA stability and 
structure can be affected, but also initiation and elongation on a translational level, as 
well as protein folding69–72. It is possible that the redundancy in the genetic code has 
evolved as an extra layer of information stored in DNA – e.g. as a method to preserve 
structural information of proteins within the nucleotide content73. Early genetic 
research revealed a positive correlation between expression levels of genes and the 
codon usage74, and several strategies for codon optimization have been developed to 
optimize heterologous genes for expression in the desired host.  
 The Codon Adaptation Index (CAI)75 is established based on a reference set of 
highly expressed genes, from which the optimal codon composition for an organism 
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can be defined. The underlying assumptions are that translational selection has 
optimized gene sequences for highly expressed genes. These genes assumingly 
compete for resources, and thus require more accurate translation75. The reference 
gene set is used to compute the weight of the codons for each amino acid. The mean 
value of all codon weight in a sequence defines their CAI-value. This means, that if a 
gene is composed exclusively of the most frequently occurring codon for each amino 
acid in the reference set, it will have a CAI-value of 1. Successful expression of genes 
designed to match host bias or maximizing CAI have been reported in many 
cases76,77.  Nevertheless, a defined relationship between these optimization strategies 
and expression has not been found78.  The simplification of codon usage in CAI has 
been criticized79, and a recent study showed that 81 synthetic genes exhibited no 
correlation between the genes’ CAI-values and their actual level of gene expression78.   
 Several prediction models have been developed to estimate the consequences 
of codon bias and tRNA availability for gene expression. One example is the effective 
number of codons: a model, which provides a measure of the extent of codon 
preference in a gene. By comparing the actual codon composition of a gene to a 
theoretical equal use of synonymous codons, an effective number of codons between 
20 and 61 is given80. Other examples include the aforementioned CAI75, and the 
tRNA adaptation index81. The tRNA adaption index is different from the other 
prediction models, because it considers the interactions between the tRNA and the 
codon, and the effects of wobble pairing, where other pairs than A-T and G-C are 
formed82 (Wobble base pairs are explained in section 1.8). Wobble pairing is very 
common for tRNA-codon interactions83, and is thus important to consider for this type 
of predictions. A recent framework also encounters several protein synthesis 
mechanisms: It is shown that for some tRNA species, there are very few molecules 
available for the translating ribosome and additionally that there is a dependency 
between the codon-specific elongation rate and the overall codon usage in the cell84.  
Recent studies have challenged some of these prediction theories. With a set of 154 
synthetic variants of green fluorescent protein (GFP), all encoding the same protein 
sequence but with varied codon compositions, the widely used prediction theories 
were put to the test69. The gene set contains sequences with both high, intermediate 
and low frequencies of rare codons. Kudla and coworkers (2009)69 showed that 
neither the CAI nor frequency of optimal codons could predict the fluorescence 
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levels. On the contrary, some of the highest expressed genes showed low CAI values.  
The study revealed that the structure of the mRNA is a determining factor for gene 
expression levels, as weaker structures around the start codon yielded high gene 
expression69.  This work was further supported when the hypothesis that rare codons 
in the 5´ end of genes may positively influence translation efficiency85 was recently 
verified86. By assaying the expression of 14.000 synthetic reporter genes with codon 
usage variation in the 5´ end, it was shown that the expression of a single gene could 
be improved up to 14-fold by exchanging N-terminal common codons for rare 
codons. Using a computational prediction of the genes’ mRNA structure, it was 
shown that a reduction in the RNA structure free energy is responsible for the 
increased expression, not the fact that the codons are rare. The link between 
expression levels and rare codons is observed, since they often contain A/T in the 
third position, which affects the folding energy of the RNA86. 
It has very recently been shown that the region containing the junction of the DNA 
and the vector, situated between the Shine-Dalgarno sequence and the start codon, has 
an impact on gene expression levels as well. By varying the sequence of the junction, 
high-level expression was achieved for genes previously difficult to overexpress, and 
the work reveals the importance optimizing or avoiding scarring sequencing when 
inserting a gene into a vector87.  
 
1.8 Structure, synthesis and function of tRNAs 
 Acting as the physical link between the genetic code and the protein sequence, 
tRNAs are essential to protein synthesis. One of 
the characteristics of tRNA molecules is the 
ability to fold into a tight structure88. A tRNA 
molecule consists of 75-90 nucleotides and the 
secondary structure of tRNAs resembles a 
cloverleaf, whereas the tertiary structure often is 
shown as an L-shape. The cloverleaf 
structure is depicted in Figure 3. The 
structure of the molecule enables the tRNA 
to fit into the ribosome. The three stems in the structure are denoted the D-stem, the 
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Figure 3 Schematic representation of a classic 
secondary tRNA structure 
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anticodon stem and the T-stem, and they each have a loop denoted the D-loop, 
anticodon loop and T-loop respectively. The T-arm (stem and loop) is the recognition 
site for the ribosome, where the ribosome-tRNA complex is allowed to form during 
protein biosynthesis. The D-arm is named after dihydrouracil, a base found in the D-
loop. This part of the tRNA is important for ribonuclease P (RNase P) recognition but 
not for interaction88. RNase P is important during tRNA synthesis, which is described 
in section 1.8. The 3’ end of the tRNA molecule carries a CCA-tail necessary for 
amino acid charging88. This sequence is also important for base pairing with RNase P 
RNA during maturation89.  The amino acid is covalently attached to the terminal 
adenosine of the tRNA. E. coli has the 3’ CCA end encoded in all tRNA genes90, but 
this is highly variable among different bacteria, and the sequence can be post-
translationally added as well. 
 
1.8.1 tRNA synthesis 
 The number of tRNAs is vastly varied in all organisms88. Moreover tRNAs are 
often in abundance, as you need less than 61 to read all codons (due to wobble 
pairing). Of the 86 tRNAs in E. coli, 26 are transcribed as monocistronic transcripts, 
where the tRNA is transcribed alone with appropriate extensions required for further 
processing. The remaining 60 tRNAs are organized in polycistronic transcripts with 
up to 7 tRNAs encoded together91. These transcripts are subsequently cleaved by 
ribonuclease P (RNase P)92.  Some of the tRNAs are encoded in rRNA operons, this is 
a common feature for bacterial rRNA operons93.  
 Initiation of transcription happens upstream and terminates downstream of the 
tRNA gene. Most tRNA species are transcribed with extensions in both the 5’ and 3’ 
end of the molecule94. RNase P is responsible for the formation of a mature 5’ end of 
the tRNA molecule, and it removes the 5’ leader sequence by specific cleavage of the 
sequence immediate upstream of the mature tRNA sequence92. RNase E removes the 
3’ extension formed upon translation by cleavage downstream of the 3’ CCA. This 
action is usually followed by digestion of the remaining nucleotides, until the 3’ CCA 
mature end of the tRNA is formed95.  
 Amino acyl-tRNA synthetases (aaRS) are responsible for the charging of 
tRNAs. The side chain of the amino acid is recognized by the aaRS, followed by 
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binding, a reaction that sometimes induces conformational changes in the aaRS. This 
increases the probability of correct tRNA binding, thus reducing the frequency of 
miss-charging. The anticodon of the tRNA is the most important feature used by the 
aaRS to ensure the tRNA matches the amino acid96.  
 
1.8.2 tRNA function 
 As mentioned, the tRNA molecules provide the link between the genetic code 
and the protein’s amino acid sequence through ribosomal and mRNA interactions97. 
Base pairing with the mRNA strand happens through the codon on the mRNA and the 
anticodon on the tRNA. Watson-Crick base pairing (A-T- and G-C-pairing) connects 
the first two nucleotides in the codon to the anticodon, while the third can form a 
wobble-pair82 (Figure 4) Wobble pairing among others depends on the hydrolytic 
deamination of adenosine to inosine, a common and often essential tRNA 
modification in the wobble position.88 Inosine can base-pair with A, U or C, and 
allows for tRNAs to pair with other codons than their most obvious partner98. There 
are four main wobble base pairs: G-U, I-U, I-A and I-C.  
 
Figure 4 Wobble pariring between tRNA and mRNA. When the first base in the anticodon is a C or G, no 
wobble pairs can form. For G, U or I in the first position of the anticodon, wobble-pairs G-U, I-A, I-U and I-
C can form. 
The tRNA carries the encoded amino acid in the other end of the molecule, and is 
referred to as 'charged'. An aaRS charges the tRNA with its cognate amino acid. The 
amino acid enters the aaRS together with ATP, followed by AMP being joined to the 
amino acid upon the release of phosphate. The tRNA takes the AMP's place in the 
aaRS, which catalyzes the formation of an ester bond between the adenosine residue 
on the tRNA and the amino acid. The charged amino acid is now released from the 
aaRS. The elongation factor EF-Tu complexed with GTP is responsible for bringing 
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the charged tRNA to the ribosome99. Entry of tRNA into the ribosome happens on a 
trial-error basis: If the tRNA does not match the mRNA codon, the tRNA is rejected. 
When the correct tRNA enters the ribosome, several conformational changes are 
performed to accommodate the tRNA100. The ribosome has three active sites: the A-
site, P-site and E-site101. Entry of tRNAs into the ribosome happens in the A-site. The 
ribosome catalyzes the formation of a new peptide bond, and the peptidyl-tRNA 
accommodated in the P-site transfers the growing peptide chain to the amino-acyl 
tRNA in the A-site. This can only happen due to the dramatic conformational change 
the ribosome undergoes. Upon formation of the peptide bond, the tRNA in the P-site 
has a free 3’ end, and the tRNA in the A-site carries the polypeptide chain. The 
conformational change of the ribosome brings the residing tRNAs to the next active 
site. The next elongation cycle can happen after binding of elongation factor G to the 
ribosome, which brings it back to a conformational state capable of receiving a new 
tRNA101.  
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Figure 5. A) Charging and release of tRNA from aaRS. A1) The amino acid  enters the active site of aaRS 
followed by ATP. Upon release and subsequencent breakdown of pyrophosphate to phosphate, AMP is 
bound to the amino acid. A2) tRNA replaces AMP in aaRS, and the syntethase catalyzes the formation of an 
ester bond between the tRNAs adenine-residue and the amino acid. A3) The charged tRNA is released from 
the aaRS and bound by EF-Tu complexed with GTP, which is responsible for bringing the charged tRNA to 
the ribosome . B) Interaction of tRNA and ribosome. B1) The tRNA entered the ribosomes A-site, and EF-
Tu, GDP and Pi are? released. B2) The tRNA in the P-site transfers the peptide chain to the tRNA in the A-
site, and the ribosome undergoes dramatic conformational change. B3) The tRNA accomodated in the 
ribosome transfers to the adjacent active site, and EF-G occupy the A-site, to bring the ribosome back to its 
RNA-accepting state. The tRNA in the E-site leaves the ribosome. 
   
1.9  Correlation between tRNA concentration and codon usage  
 When the degeneracy of the genetic code became apparent, and understanding 
of the central dogma was refined, vivid discussion on the correlation between the 
concentration of tRNAs and the usage of codons took place. It is a complex subject. 
In BL21, there are 86 tRNA genes as mentioned above. They are used to recognize 61 
Ribosome
Ribosome
   
   
EF
-T
u
A
C
C
A
C
C
a.a
a.a.
aaRS
aaRS
a.a
aaRS
Peptide chain
mRNA
GTP
Ribosome
mRNA
Peptide chain
mRNA
Peptide chain
EF-G
E     P     A
E     P     A
E     P     A
A B
2
11
3
2
3
a.a
aaRS
AMPATP
Pi
Pi
Pi
.
Chapter 1 
19 
codons, and charged by 20 amino acyl tRNA syntethases102. To add even more 
complexity, many tRNAs can recognize several different codons, due to wobble base 
pairing82.  
 
 
Figure 6 Schematic representation of the complex relationship of aaRS, tRNAs, codons and amino acids. 20 
aaRS share the task of charging 86 tRNAs with 20 amino acids, encoded by 61 codons.  
 Early research suggested that there is a strong relationship between the codon 
usage and the tRNA pool103, and the hypothesis of codon adaptation to the tRNA pool 
was confirmed by Ikemura65, to some extent this work explained the codon bias in 
highly expressed genes. The understanding of tRNA gene copy number and codon 
usage evolution became more sophisticated when the co-evolution of tRNA 
abundance and codon usage was analyzed by Michael Bulmer in 1987104. With a 
focus on E. coli and yeast, he suggested that rapid division, which causes a strong 
selection pressure, could partially explain the high codon bias observed in some 
genomes like E. coli and S. cerevisiae. The distribution of tRNA abundance has also 
been shown to vary with the growth rate of E. coli, and can be roughly correlated with 
the bias of the mRNA population105. The tRNA population in a cell thus closely 
reflects the codon bias of the mRNA population105. So when the growth rate of a cell 
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culture increases, the tRNA species cognate to abundant codons increase in 
concentration. Most tRNAs cognate to less abundant codons remain constant105.  
 The charging of tRNAs if efficient as the charged fraction of all tRNAs are 
approximately 80% during exponential growth106. The rate with which the ribosome’s 
A-site is filled closely reflects the concentration of the tRNA able to read the present 
codon. In the case where an amino acid becomes the limiting factor for protein 
synthesis, it may happen that the charged fraction of its tRNAs drop dramatically106. 
 
1.10 The pRARE plasmid 
 One of the popular E. coli strain choices for heterologous gene expression is a 
commercial strain called Rosetta, available from Merck Millipore (previously 
Novagen)107. The strain comes in DE3 and pLysS versions, and is characterized by 
the tRNA-supplying plasmid called pRARE. This plasmid is a key component of the 
experimental work presented chapter 2 where the effects of co-expressing this 
plasmid for increased protein production are investigated, revealing that co-
expression of pRARE has very little effect on the production of a large number of 
membrane proteins in E. coli, and that the plasmid can cause impaired growth. We 
additionally show that other factors than the tRNAs may very well be responsible for 
positive effects on recombinant protein production. 
 Since the plasmid is a commercial product, not much is found about it in the 
literature. With a curiosity about the design of the plasmid, we decided to sequence it 
to gain a better understanding of the design. The pRARE plasmid is shown in Figure 
7 together with the parent plasmid pLysS68. The major elements on the two plasmids 
are the p15A origin giving a plasmid copy number of 10-12108, the chloramphenicol 
resistance gene, and the T7 lysozyme encoding gene. The plasmid additionally carries 
the tRNA sequences for the 7 tRNAs cognate to the most rare E. coli codons68. 
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Figure 7 Schematic representation of pLysS and pRARE. Not drawn to scale. Both plasmids contain T7 lysS 
(blue), p15A (purple) and cat (blue), and pRARE additionally contains 7 rare (yellow) and 5 non-rare 
tRNAs (beige). The tRNA promoters are placed based on assumptions from the analysis of pRARE.  
 
 The cat gene encodes chloramphenicol acetyltransferase, which infers 
resistance to chloramphenicol. This enzyme catalyzes the formation of a covalent 
bond between an acetyl group from acetyl CoA and chloramphenicol, which disables 
the binding of chloramphenicol to the 30S subunit of the ribosome. In absence of 
chloramphenicol acetyltransferase, this bond would inhibit cell growth preventing 
protein production109.  
  pRARE carries a set of tRNAs designed to compensate for minor tRNA 
species in E. coli during heterologous gene expression. They are under the control of 
their native promoters. Several of these can form wobble pairs, shown in Table 2 
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Table 2. List of tRNA genes present on pRARE, their anticodons and respective codons recognized either 
through Watson-Crick or wobble pairing. Rare codons are shown in bold. *IleX can pair with AUA due to 
lysinylation of the C-residue.  
tRNA gene anticodon codon(s) 
argN5 UCG CGA/CGG 
argX CCG CGG 
proL GGG CCC/CCU 
leuW UAG CUA/CUG 
metT CAU AUG 
argW CCU AGG 
thrT GGU ACC/ACG 
glyT UCC GGA/GGG 
tyrU GUA UAC/UAG 
thrU UGU ACA/ACG 
argU UCU AGA/AGG 
ileX CAU* AUA* 
 
It appears that the genes have been directly transferred from the genome of E. coli 
BL21 to this plasmid, as several of them are accompanied by non-minor tRNAs 
which they are co-transcribed with in the genome. The genomic arrangement of the 
rare tRNAs are shown in Figure 8, which account for the expected source of 11 of the 
12 tRNAs found on the pRARE plasmid. The tRNA gene argN5 is not accounted for, 
since it is not found in the genome of BL21. ArgN5 is cognate to the rare codon CGA, 
and found in the E. coli strains O111:H- str. 11128 and O157:H7 str. Sakai, two 
pathogenic E. coli strains110. BL21 does not have a tRNA with the UCG anticodon for 
decoding of the rare CGA codon - this is translated by pairing with an ICG 
anticodon111.  
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Figure 8 Schematic representation of the genomic arrangement of tRNAs present on pRARE . Blue boxes 
illustrates the approximate part of the genome that is assumed to have been transferred to pRARE. A) argX 
B) proL C) leuW D) argW E) glyT F) argU G)ileX. 
 
 When we comparing the sequence of the pRARE plasmid to the genomic 
DNA containing the tRNAs, several observations were interesting regarding the 
design of pRARE. The tRNA genes argX and argW are found on pRARE with their 
respective promoter sequences from the genome, and apart from the 5’ leader 
sequence, they are not accompanied by any additional coding sequence. To some 
extent this goes for proL as well, but pRARE additionally contains DNA aligning to 
the 3’ end of the upstream gene yejM. In pRARE the tRNA genes leuW and glyT are 
both found in operons with other tRNA genes, likely to ensure the transcription from 
their native promoters. LeuW is accompanied by the tRNA gene metT, and for glyT, 
the full operon containing 4 tRNA genes is found in pRARE. In the genome, the 
promoter for this operon is buried in the 5’ end of an upstream, reverted gene, and 
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likewise, the pRARE contains DNA that aligns to this part of the genome. In the 
pRARE plasmid, ileX is encoded in the opposite direction of all other tRNA genes. 
Curiously, the native promoter does not seem to be present on pRARE. However, it is 
possible to detect a -10 and -35 region, which most likely serve as a promoter for ileX, 
immediately related to the gene in the plasmid. The base pairing between ileX and its 
cognate codon is special: ileX carries the anticodon for methionine (AUG), but the C 
residue is lysinylated and this reaction modifies the residue to lysidine, a derivative of 
cytidine112, subsequently allowing AUA base pairing rather than AUG. This is a 
posttranscriptional modification which is essential for acylation by isoleucyl tRNA 
synthetase with leucine, as well as the AUA codon recognition113. The success of 
overexpressing tRNA genes from this plasmid to achieve high titers of functional 
protein is different to evaluate to an inherent bias against failed experiments in the 
literature. In our hands, outcomes of experiments have been difficult to predict, and of 
high variability. The pRARE plasmid is a complex construction and the rationale 
behind the design is not available in scientific literature. In the parent plasmid, pLysS, 
PΦ3.8 is recognized by T7 to transcribe around the plasmid resulting in minor levels of 
lysozyme. The importance of increased plasmid size for lysozyme levels has never 
been investigated, and this is discussed in further detail in chapter 2. This chapter also 
discusses how some of the issues encountered with recombinant protein production in 
the pRARE in our hands can be explained by some of these details presented here 
about the plasmid.  
 
1.11  History of tRNA-supplying plasmids  
 The use of extra copies of minor tRNA species to increase heterologous gene 
expression started with Brinckmann and co-workers who co-expressed the tRNA gene 
dnaY (now known as argU) with eukaryotic genes known to express poorly in E. 
coli114. The genes had a high content of AGA and AGG codons, which are recognized 
by tRNAAGG/AGA produced from dnaY. When supplying dnaY on a plasmid, 
improved accumulation of product up to 30% of total cellular protein was achieved114. 
The levels of the dnaY gene product were shown to have significantly increased when 
supplying the gene on a plasmid, and inactivation of dnaY by deletion resulted in the 
same phenotype as strains lacking the extra copy of the tRNA gene.  
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 The approach was further developed when the plasmid PRI952 expressing 
both dnaY and the rare ileX tRNA gene was used to increase the expression of a flu 
antigen in E. coli113. Interestingly, the results show a slightly diminished level of 
expression when both dnaY and ileX were supplied on a plasmid, compared to merely 
ileX-supply. The authors do not go into further analysis of this observation, but for the 
work presented in chapter 2, this is highly relevant: We observe a similar and much 
more pronounced effect where the supply of several tRNA genes on a plasmid 
strongly diminishes the expression of a gene containing several rare codons. When the 
tRNA genes are not co-expressed, gene-expression is recovered.  
 The plasmid PRI952 was further developed and used for expression of parasite 
genes, which are known to have a high AT-content115. With the addition of glyT to the 
plasmid, creating pRIG, the supply of minor tRNAs cognate to rare arginine-, 
isoleucine-, and glycine-codons, improved the expression levels of the parasite-genes 
significantly115. The glyT gene was amplified from an E. coli genome: Although the 
source is not specified, but for both K-12 and BL21 (and derivatives), the region 
surrounding this gene is conserved. Our assesment of the sequences of the 
oligonucleotides used to amplify the glyT gene revealed that the other 3 tRNAs co-
transcribed with glyT are also transferred to pRIG, and these tRNAs are very likely to 
play a role in the obtained results as well.  
 One of the first commercial tRNA-supplying plasmids, pRIL116, contains the 
tRNA genes argU, ileY, and leuW, and is supplied as an expression system in 
BL21(DE3). Curiously, unlike the K-12 MG1655 strain, BL21(DE3) has no ileY gene 
encoded in the genome, but the corresponding variant ileX is 97% identical, and 
carries the same anticodon. This plasmid has been used to study the effects of 
changing the concentration of tRNA on protein folding and solubility116. The results 
showed that the tRNAs are up-regulated between 5- and 27-fold, and additionally, 
that the concentrations of other genome-encoded tRNAs is not affected. The cell-wide 
study also shows how several proteins suffer from altered solubility, increasing the 
probability for them to end up aggregating, thus non-functional116.  
 The commercialization of the concept tRNA overexpression has been 
extended and several companies offer tRNA-supplying solutions, examples are in the 
CodonPlus and Rosetta strain collections. The strains in these collections carry a 
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plasmid supplying tRNAs for the most rare codons in E. coli, offering "universal 
expression" of eukaryotic genes68,117. 
 In a recent large-scale protein production project, the Human Protein Atlas 
Project, changing the bacterial expression strain from the traditionally applied BL21 
to the tRNA-supplying Rosetta improved the overall yields and success rate118. 
Following up on this work, the effect of different promoters in the two expression 
strains was tested, suggesting that Rosetta generally supported higher expression, 
regardless of promoter choice119.  However, surprisingly, no correlation between 
(rare) codon content and effect of tRNA supply was observed in these studies119.  
 
Paper I  
 This thesis provides a deeper understanding of the effects of the different side 
effects that may be encountered when attempting to increase protein production levels 
in bacteria. Chapter 2 reports the surprisingly small effects of supplying additional 
copies of low-abundance tRNA on a large set of membrane protein encoding genes. 
We expressed a library comprised of more than 300 E. coli inner membrane protein-
encoding genes fused to GFP, to systematically study the effect of tRNA 
complementation in a high-throughput manner. To our surprise, the majority of the 
constructs showed little difference in expression with and without pRARE, and upon 
this discovery we initiated the search for genes that would be influenced by tRNA 
complementation. The results of expressing of a set of synonymous codon variants 
encoding a GFP-derived fluorescent protein caught us by surprise: Contrary to 
expectations, the presence of pRARE yielded a dramatic drop in expression levels. 
Upon construction of pRARE-derived plasmids either lacking all tRNAs or the T7 
lysozyme gene, we show that the presence of additional tRNA copies can have a 
negative effect on heterologous gene expression, as no inhibitory effect on expression 
or growth was observed in absence of tRNAs on the pRARE backbone. Moreover in 
the absence of the lysS gene, the inhibitory affect was preserved in pRARE compared 
to pLysS. Still urging to investigate the positive effects of tRNA complementation, 
we noticed that several plant cytochrome P450 genes and a human breast cancer-
related gene seemed to be positively affected in expression by the pRARE plasmid. 
Our initial experimental setup confirmed the positive effect of pRARE, but removal 
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of the tRNA encoding regions of pRARE resulted in a further increase in expression 
from both constructs. The lysS gene present on both pRARE and pLysS encodes T7 
lysozyme. To the contribution of lysS to expression levels, expression of lysS-less 
plasmids revealed even higher expression levels than with the tRNA-less pRARE. 
This suggests that the major difference between the effect of pRARE and pLysS is 
caused by lysS. These phenomena seem to have been largely overlooked despite the 
huge popularity of the T7/pET-based systems for bacterial protein production. 
 
1.12  Standardized cloning strategies 
 One of the key drivers for biological research has been the ability to cut and 
paste DNA in a controlled manner from different sources, and successively assemble 
these parts into gene constructs, also known as cloning. Advances in molecular 
biology are moving fast, but cloning remains a bottleneck, as it is time consuming and 
unpredictable. For production of complex compounds, the expressing of a single gene 
is often not sufficient, as the cells machinery do not provide all precursors. This is 
particularly a challenge when choosing unicellular organisms for cell factories such as 
E. coli and S. cerevisiae, as they often have a less versatile metabolism. To overcome 
the limitations of these hosts, introducing a full pathway for synthesis of the desired 
compound can be the solution. To introduce a whole pathway into a host strain, a 
great amount of cloning and subsequent optimization is required. Substantial efforts 
have been invested into developing new tools for DNA assembly, to increase the 
standardized format, and ensure improved, low-cost DNA assembly120. With 
decreasing cost of gene synthesis, the cloning-bottleneck is minimized, and the 
advanced techniques for DNA assembly makes building libraries and larger multi-
gene constructs even more feasible121.  
 
 
With strategies like Gibson Assembly121 and Golden Gate cloning122, which both 
offers multi-fragment cloning in a single tube, it has become possible to tackle 
projects of increasing scale and complexity. Challenges still remain, as 
standardization often comes with the cost of flexibility, and to move into the future of 
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cell factories, the bottlenecks involved in cloning must be overcome, offering an even 
more generic standardized solution. We have addressed the paradox of sacrificing 
flexibility in exchange for optimized standardization in PaperII, which is presented 
here.  
 
PaperII 
 In chapter 3, the work of Morten Thrane Nielsen, Susanna Seppälä, myself 
and others is presented, and it covers the development of a standardized method for 
multi-gene assembly. Production of the red compound protoporphyrin IX is applied as 
a proof-of-concept, due to the easy initial screening with a visible output. We have 
created a cloning strategy that allows for standardization at two levels. By defining an 
entry format and subsequent general downstream assembly strategy, the platform 
allows for faster cloning cycles. We utilized the cloning pipeline to explore aspects of 
pathway engineering in E. coli using protoporphyrin IX as test case. In two simple 
design-build-test cycles we managed to achieve state of the art levels of 
protoporphyrin IX production (50 mg/L). Besides easy assembly of genes, we 
optimized the level of expression through randomization of the Shine-Delgarno 
sequence, incorporating differentiated affinity in the ribosome binding site. The 
pipeline supports easy combination of standardized genes, and makes it easy to obtain 
full functioning pathways in E. coli, enabling a shorter optimization process. 
 
1.13 High-value compound production in E. coli 
 To obtain full-length functional proteins and enzymes from heterologous 
expressed genes is another major challenge in the biotechnology. This can especially 
be challenging when they are membrane bound in their original host, as membrane 
properties varies greatly. Recent advances in recombinant protein production has 
allowed for the production of several high value products in E. coli, including several 
therapeutic proteins12,123. However, the production of numerous valuable compounds 
is restricted by the successful expression of genes encoding important enzymes 
involved in their biosynthesis. These products include terpenoids, alkaloids and 
phenylpropanoids, which are often produced as secondary metabolites in plants. They 
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have applications in several fields such as human health and nutrition124, and their 
complex structures are difficult to obtain through chemical synthesis. They often 
contain complex core carbon skeletons which are stereo specifically hydroxylized,, 
and this task is completed by cytochrome P450 monooxygenases (P450s)124. The 
production of isoprenoids and likewise compounds in microbial hosts as an alternative 
to engineered plants is attractive, as they are much cheaper to grow, less susceptible 
to contamination, and downstream processing from microbiel sources is usually 
easier125. However, many obstacles must be overcome to achieve functional microbial 
expression of the genes responsible for biosynthesis of an isoprenoid of interest. The 
major limitation lies within the expression of P450s: so far, no reliable guidelines are 
developed for microbial P450 expression, and one of the challenges in obtaining 
functional enzymes are their putative dependency on membrane integration, as well as 
their dependency on redox partners126. 
The efficient expression of P450s requires a systematic assessment of the 
proper expression conditions. In Paper III we have contributed with a platform, from 
which several plant P450s have been expressed succesfully in our hands.  
 
PaperIII 
Chapter 4 contains the joined efforts of Ulla Christensen, Dario V. Albacete, 
myself and others, where we develop and test a platform for optimized expression of 
P450s in E. coli. Functional P450s are achieved by very simple means. The addition 
of a carboxy-terminal GFP yielded a visible out that could be easily assayed and 
optimized in several iterations, and the setup is very suitable for expression screening 
in a larger scale. We applied an N-terminal tag of 28 amino acids previously known to 
improve gene expression in E. coli and tested the effect of exchanging the P450s 
native membrane anchor for an anchor derived from an E. coli membrane protein 
gene. Additionally, we tested several growth media and strains, and determined a set 
of optimal conditions for P450 expression in E. coli. We show the efficiency of the 
platform by expressing six P450s originating from plants, and for all genes, we were 
able to achieve full-length, functional proteins. The work shows how a GFP-reporter 
approach can be useful for optimizing expression of P450s in E. coli, and shows that 
there is no inherent limitation for applying different types of strains.  
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1.14 Future perspectives on cell factories 
 Biotechnology has come a long way since the first cell factories were 
developed in the early 80's, and the fast-paced technology development decreases the 
time and money spent on cell factory development. One of the future perspectives for 
biotechnology is the technology to synthetically construct a fully functioning genome, 
which will allow for increased system control to increase production of a compound 
of interest. The initial steps towards synthetic genomes have already been taken: the 
genome of a small virus that infects bacteria was synthetically constructed in 2003127, 
and the first synthetic yeast genome was revealed in 2014128. This work emphasizes 
how easy and well-functioning standardized DNA assembly techniques have become, 
as undergraduate students constructed most of the DNA fragments. A new era of 
biology based on the redesign of genomes is emerging, and the way has been paved 
by this work. However, the heavy manual workload to construct synthetic genomes 
has to be dramatically reduced, and this will likely happen as more automated labor 
are introduced in laboratories. Additionally, when the price for DNA synthesis 
decreases dramatically, we will probably see a slowly emerging paradigm shift. It is 
unlikely that DNA cloning will be completely phased out; the flexibility, rapidness 
and accessibility is valued by scientists, and a shift in mindset will probably happen 
over several decades. Another future perspective is the expanded use of cell-free 
systems. The power of cell-free systems has been valued for more than 100 years129, 
but has far from reached its full potential yet. By avoiding complex balancing of the 
cells and the scientist’s objectives, the cellular resources can be focused towards an 
exclusive user-defined objective. Cell-free systems can be exploited to increase the 
understanding of Nature’s way, and furthermore, the capabilities of cells can be 
exploited without having to nurture their needs. In the time between now, and until 
these and other advances are readily available for the majority of researchers, the 
classic way of developing cell factories is challenged all the time, i.e. through new 
cloning methods, strain design and better understanding of gene transfer between 
organisms. It is naive to believe that a complete shift to sustainable solutions can be 
achieved through biotechnology, but giant leaps in the right direction are taken, and 
this at least postpones the exhaustion of the planets resources.  
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Recombinant protein production is at the core of biotechnology and numerous 
molecular tools and bacterial strains have been developed over the past four decades 
for this purpose. A major challenge is the degeneracy of the genetic code, causing 
many genes to express poorly. One attempted generic solution is to supply with extra 
copies of low-abundance tRNAs to compensate for the presence of complementary 
rare codons in genes-of-interest. Here we show that such extra tRNA, supplied by the 
commonly used pLysSRARE2 plasmid, has very little effect on the production of a 
large number of membrane proteins in E. coli. Further, we observe two types of side 
effects: in some cases growth and gene expression is directly impaired by the extra 
tRNA sequences and in other cases the apparent positive effects are instead caused by 
a differential expression of the lysozyme gene encoded on the same plasmid. Next 
generation RNA sequencing of a strain containing the pLysSRARE2 plasmid reveal 
that several of the tRNA molecules are transcribed in the antisense orientation 
providing a possible explanation to the observed negative effects and the lack of rare 
codon complementation. These phenomena seem to have been largely overlooked 
despite the huge popularity of the T7/pET-based systems for bacterial protein 
production. 
Chapter 2 
 40 
2.1 Introduction 
The genetic code is degenerate and between one and six different codons can encode 
a single amino acid. The frequency for using a specific codon varies between different 
organisms - a phenomenon referred to as codon bias. This has long been recognized 
as a major challenge in heterologous gene expression, as the host might not transcribe 
and/or translate the foreign DNA sequence in an optimal manner. Partly, this may be 
caused by a parallel low abundance of tRNAs cognate to codons that are low in 
frequency – these codons are commonly referred to as rare codons1. 
Numerous studies have shown that synonymous codon mutations can have 
drastic consequences for gene expression. Factors such as mRNA stability and 
structure can be affected, but also initiation and elongation of translation, as well as 
protein folding2–5. It is possible that the redundancy in the genetic code have evolved 
as an extra layer of information stored in DNA – e.g. as a method to preserve 
structural information of proteins within the nucleotide content6. It is important to 
note that rare codons can be an advantage; the hypothesis that rare codons in the 5´ 
end of genes may positively influence translation efficiency7 was recently 
corroborated by assaying the expression of 14.000 synthetic reporter genes with 
codon usage variation in the 5´ end8.  
 Several strategies have been developed to optimize genes for expression (for 
recent reviews on the topic see 9–14), but the success rate is hard to gauge due to the 
inherent bias against negative results in scientific literature15. An attractive alternative 
to DNA re-coding is overexpression of low-abundance tRNA species. This way, the 
host, rather that the individual genes, is harmonized towards an ideal gene expression 
chassis. In one example, Brinckmann and co-workers coexpressed dnaY (now known 
as argU) with eukaryotic genes known to express poorly in E. coli16. The genes had a 
high content of AGA and AGG codons, which are recognized by tRNAAGG/AGA 
produced from dnaY. Upon supplying dnaY on a plasmid, improved accumulation of 
product up to 30% of total cellular protein was achieved16. A variant of the approach 
was later used for expression of parasite genes, which are known to have a high AT-
content, and addition of a plasmid supplying minor tRNAs cognate to rare arginine-, 
isoleucine-, and glycine-codons, improved the expression levels significantly17. The 
concept of tRNA overexpression has been further developed and commercialized, and 
several bacterial strains are available offering "universal expression" of eukaryotic 
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genes18. In a recent large-scale protein production project, the Human Protein Atlas 
Project, changing the bacterial expression strain from the traditionally applied BL21 
to the tRNA-supplying Rosetta improved the overall yields and success rate19. 
Following up on this work, the effect of different promoters in the two expression 
strains was tested, suggesting that Rosetta generally supported higher expression, 
regardless of promoter choice20.  However, curiously, no correlation between (rare) 
codon content and effect of tRNA supply was observed in these studies20.  
 As with codon optimization, bias in the way science is published, makes it 
hard to evaluate the global success rate of an approach such as (rare) tRNA 
complementation. Here, we compare the homologous expression of a large set of 
membrane protein (MP) encoding genes and observe surprisingly small effects of 
supplying additional copies of low-abundance tRNA. Moreover, in searching for 
genes that are affected by tRNA supply, we find examples where a tRNA supplying 
plasmid have a direct negative effect on gene expression, and examples were other 
factors in the tRNA supplying plasmids are the main causative elements. 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
AU: Arbitrary units; MP: Membrane proteins; GFP: Green fluorescent protein
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Results 
Additional tRNA copies have no dramatic effect on homologous production of MPs in 
E. coli 
The green fluorescent protein (GFP) is a highly useful reporter of proper folding and 
targeting of MPs15. When GFP is fused to the C-terminus of a MP, misfolding or 
mislocalization of the MP will effectively quench the fluorescence from the attached 
GFP. In contrast, a properly expressed MP-GFP, with the C-terminus in the cytoplasm 
(Cin), can be monitored by simple fluorescence detection techniques21. A library of 
nearly all E. coli multispanning MPs, C-terminally fused to GFP in a common pET-
based expression vector system was previously developed by Daley and coworkers22. 
To systematically study the effect of tRNA complementation, we reduced this library 
to the extent that it finally contained only the Cin inner membrane proteins which 
made it compatible with a fluorescent readout of expression. We then transformed the 
individual clones into both BL21(DE3) pLysS and the BL21-derived strain 
RosettaTM2(DE3) that harbours the pLysSRARE2, a rare tRNA-supplementing 
plasmid derived from pLysS23 (Fig. 1a), and assayed protein production by whole cell 
fluorescence in a 96-deep well format.  
 
 
Figure 1. A) Schematic representation of pLysS and pRARE, not drawn to scale. On both plasmids: T7 lysS, 
PΦ3.8, cat. On pRARE: 7 rare tRNAs (grey) and 5 non-rare tRNAs (white). B) Compared expression of ~300 
membrane protein encoding genes in Rosetta2(DE3)pLysS on the X-axis and BL21(DE3)pLysS on the Y-
axis. Units are fluorescence (arbitrary units)/OD600nm.  
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To our surprise, the majority of the constructs showed little difference in protein 
production in the two strains (Fig. 1b):  approximately 10% of the MPs were 
produced more than 2-fold in RosettaTM2(DE3).  In contrast, only less than 2 % of the 
MP output was more than 2-fold better in BL21(DE3) pLysS. Apparently, tRNA 
complementation with pLysSRARE2 has no dramatic effect on overproduction of 
homologous MPs in E. coli. 
 
Additional tRNA copies can have a negative impact on heterologous gene expression 
In searching for genes that would be influenced by tRNA complementation, we came 
across a set of synonymous codon variants, encoding a synthetic GFP variant named 
DasherGFP (excitation and emission wave length at 510nm and 521nm respectively), 
expressed from a still inducible but reduced version of the rhamnose promoter 
prhaBAD. These variants were designed by scientists at DNA2.0, Inc. (Claes 
Gustafsson and Mark Welch, personal communication) to explore the effect of rare 
codons on protein production.  In contrast to our expectations, several of the tested 
DasherGFP variants showed a remarkable drop in their production in presence of 
pLysSRARE2 in a number of different expression strains and growth conditions. We 
decided to study this further and focused on the DasherGFP25 variant that contains a 
total of 13 rare codons (out of 258 codons in total). In a representative experiment, we 
co-transformed the DasherGFP25 construct together with pLysSRARE2 or the pLysS 
control into BL21(DE3). By diluting an overnight culture, we started all expression 
cultures from OD600 0.05 and let them grow at 37°C to their exponential phase (OD 
0.3 – 0.8) where the expression of DasherGFP25 was induced by adding 2 mM L-
rhamnose. After 4 hours of induction, protein production levels were estimated by 
whole cell GFP fluorescence in a plate reader. As observed in our pilot experiments, 
the presence of pLysSRARE2 had a major inhibitory effect on produced 
DasherGFP25 , showing approximately 15-fold less production under these 
conditions (Fig. 2a). Additionally, we observed that the growth rate of the expression 
strain was significantly affected under these conditions, suggesting a fitness cost 
caused by the presence of the pLysSRARE2 plasmid.  
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Despite the overall similarity with pLysS (Fig. 1a), apart from the tRNA genes, 
pLysSRARE2 contains additional elements included in the tRNA-encoding region of 
the plasmid that could influence heterologous gene expression or the bacterial cell 
physiology. In order to proof this and for having a control for the effect of tRNAs, we 
deleted all tRNA coding sequences from the plasmid (pLysSRARE2-tRNAless), 
creating a pLysS-alike plasmid, and co-transformed this construct with the 
DasherGFP25 construct. In the absence of all tRNAs, no inhibitory effect on protein 
prodution or growth was observed (Fig. 2a). To test the effect of the lysS gene, we 
also clone a pLysSRARE2 version without the lysS gene (pLysSRARE2-lysless). 
Here, in the absence of lysS, the inhibitory affect was preserved compared to 
pLysSRARE2-tRNAless and pLysS (Fig. 2a). We conclude, the presence of 
additional tRNA copies can have a negative effect on heterologous protein 
production. 
 
Elements other than tRNAs in pLysSRARE2 may play a significant role in boosting 
heterologous gene expression 
We broadened our search for genes relying on pLysSRARE2 for proper expression 
and noticed that several plant cytochrome P450 genes and a human breast cancer-
related gene fragment BRCA1 (Alex Toftgaard Nielsen and Ariane Zutz, personal 
communication) seemed to be positively affected in expression by the pLysSRARE2 
plasmid. Here, we focus on the P450 CYP720B4 from the plant Pinus sitchensis 
involved in the biosynthesis of resin acid, a secondary metabolite involved in the 
defense against insects24 and a fragment of BRCA1, a protein that plays a role in 
maintaining genomic stability and acts as a tumor suppressor.  
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Figure 2. A) Fluorescence (arbitrary units)/OD600nm barcharts for A) dasher25, b) CYP720B4 and C) 
BRCA1 expressed in pRARE, pLysS, pRARE-LysS, pLysS-LysS and pRARE-tRNAs. D) Schematic 
representation of constructs of PT7-BRCA1 translationally coupled to mCherry, PT7-CYP720B4 linked to gfp, 
and Prha-dasher25 
 
Both expression constructs are based on the common T7 promoter, figure 2d, and the 
CYP720B4 membrane protein is fused to GFP in constructs identical to those in the 
described E. coli MP library, whereas proper BRCA1 translation can be followed 
using fluorescence due to a translationally coupled red fluorescent protein. Our initial 
experimental setup confirmed the positive effect of pLysSRARE2; CYP720B4 and 
BRCA1 expressed to 4- and 130-fold higher levels, respectively, compared to the 
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pLysS-controls (Figure 2b and 2c). However, to our surprise, removal of the tRNA 
encoding regions of pLysSRARE2 (the pLysSRARE2-notRNAs plsamid) resulted in 
a further increase in expression from both constructs. Thus, it appears that the positive 
effect of pLysSRARE2 could not be attributed to the extra tRNA copies. T7 
lysozyme, encoded by the lysS gene on both pLysSRARE2 and pLysS, inhibits T7 
polymerase25, and thus could be a contributing factor in the differential expression of 
genes controlled by the T7 promoter. As an additional control we therefore assayed 
CYP720B4 and BRCA1 expression with pLysSRARE2 and pLysS variants where we 
had deleted the lysS gene. With the lysS-less pLysS variant, CYP720B4 expressed at 
even higher levels than with pLysSRARE2-tRNAless suggesting that the major 
difference between the effect of pLysSRARE2 and pLysS was caused by lysS 
(Figure2b). With BRCA1, the effect of LysS was also apparent as the expression 
increased more than 150-fold upon removing lysS from pLysS. Despite the fact that 
pLysSRARE2 is directly derived from pLysS, preserving the entire lysS gene and 
surrounding sequence, including the Φ3.8 promoter that drives expression of lysS23 it 
is not surprising that lysS-effects differ between the two plasmids. The Φ3.8 promoter 
is placed downstream from the lysS gene and thus T7 RNA polymerase will only 
transcribe lysS after having transcribed the entire plasmid sequence present upstream 
from lysS23. In the case of pLysSRARE2, this includes all the tRNAs sequences 
(Figure 1a) and a total of 2774 nucleotides in addition to those present in the 
corresponding region in pLysS. To confirm the difference in expression of lysS from 
pLysS and pLysSRARE2, we probed the presence of T7 lysozyme by semi-
quantitative western blotting and observed that it was nearly completely absent from 
cells harbouring the pLysSRARE2 plasmid compared to pLysS (Figure 3a). To probe 
the functionality and consequences of the pLysSRARE2 plasmid more broadly, we 
expressed a dasher gene for 4 hours in BL21DE3 with pLysSRARE2, or pLysS, and 
isolated and sequenced the total RNA from these two strains. Although many genes 
appeared to express differently in the two strains, we were unable to identify clear 
trends of differentially expressed genes characteristic for specific physiological 
responses such as stress or starvation (Supplementary Information Table S1). Since 
T7 RNA polymerase needs to transcribe the majority of the pLysSRARE2 plasmid to 
reach the lysS gene, it could have a major impact on the way the tRNAs are 
transcribed from the plasmid too. Interestingly, the RNA sequencing analysis showed 
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that the two tRNAs placed immediately downstream from the Φ3.8 promoter and the 
cam resistance gene (argX and argN5) were expressed to very high levels compared 
to the pLysS strain (Figure 3b). This seems to confirm that tRNA genes are over 
expressed from the pLysSRARE2 plasmid. However, when analysing the strand 
specificity of the sequencing, more than 99% of the RNA sequence originated from 
the antisense strand of argX and argN5 and, thus, will not lead to functional tRNA 
molecules.  
 
Figure 3. A) Immunoblot of T7 lysozyme for pRARE and pLysS. B) Sense (grey) and anti-sense (white) read 
counts from RNA sequencing for all tRNA genes from pRARE. 
 
The tRNA genes downstream from of argX and argN5 were not expressed to the 
same high levels and the strand specificity was not as prominent, although the 
significant proportion of sequence from the antisense strand of several of the other 
tRNAs is worth noting (Figure 3b). 
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2.2 Discussion 
It has previously been noted that tRNAs are post-transcriptionally modified 
and amino-acetylated, and these processes must be essential for complementation of 
low-abundance tRNAs and could have metabolic side affects in the cell26. Indeed, 
Fedyunin and co-workers showed that when expression of specific tRNAs was 
upregulated between 5- and 27-fold, several proteins in the cell suffered from altered 
solubility, making them aggregation-prone27.  It is likely that the apparent negative of 
impact of pLysSRARE2 on growth and on expression of dasher is related to such 
metabolic side effects, although our RNAseq analysis gave no specific clues in this 
direction. Instead, our analysis seems to point to an apparent design flaw in the 
pLySRARE plasmid: T7 RNA polymerase transcribes major parts of the plasmid 
from the Φ3.8 promoter, leading to antisense versions of several of the encoded 
tRNAs. ArgX recognizes CGA and CGG – two of the most rarely occurring codons in 
E. coli28 – and it appears that heavy over expression of the antisense version of this 
tRNA can only make things worse. As showed here, another consequence of the 
pLysSRARE2-LysS design is that lysS is expressed at much lower levels than in 
pLysS. This is probably a direct consequence of the extra DNA added between the 
Φ3.8 promoter and lysS in pLysSRARE2. In line with this, we observe in the RNAseq 
data that the levels of (antisense) tRNA decrease with the distance to the Φ3.8 
promoter (Figure 3b) Given that T7 lysozyme directly inhibits T7 RNA polymerase, it 
is therefore no surprise that genes expressed from the T7 promoter express very 
differently when combined with either pLysS or pLysSRARE2 – as shown here for 
two very different genes and expression constructs. Given the huge popularity of the 
T7/pET-based expression systems, it is obviously important to know if the developed 
tools work as intend. There still seems to be very little direct proof available for the 
efficiency of tRNA overexpression in providing “universal expression”.  
2.3 Materials and methods  
Bacterial strains 
Escherichia coli strain NEB 5-alpha (New England BioLabs, Ipswich, USA) was used 
for cloning of PCR products and propagation of plasmids. The following E. coli 
strains were used for gene expression: RosettaTM2(DE3) pLysS and BL21(DE3) 
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pLysS (Novagen, Merck Millipore, Germany), homemade BL21(DE3) competent 
cells 
DNA constructs  
tRNA genes were removed from pRare using the following USER oligonucleotide 
sets 
5'AGTCGGTGUCATCCTGGAACTCGGCTACCTGATTTTC3' 
3'ACACCGACUAAGATGTGCTGATATAGCTCAGTTGGTAGAG5' 
5'ATCGATUCCAGCGGCCGCAAAGGCT3' 
3'AATCGAUTGGATTATAAAGTAACTCCGTGTC5' 
5'ATCATCGAUCAATGCGGCATGAGTATACCCGCTAATG3' 
3'ACACCGACUTTACAATTCAATCAGTTACGCCTTCTTTATATCCTC5' 
5'AGTCGGTGUCGTTGATACCGCAATGCGGTGTAATC3' 
3'ATCGATGAUATTTTGAACCCCGCTTCGGCGGGGTTTTTTG5'  
and T7 lysS was removed from pRARE and pLysS using the following USER 
oligonucleotides  
5'ATATACGUGGTTTCCCTTTGTTCGCATTGGA3' 
3'ACGTATAUTATTTCTTTCCTCCTTTCCTTTTTAATCTATCAAA5' 
followed by assembly with uracil excision technology as previously described (Nour-
Eldin et al., 2006; Nørholm, 2010)28,29. 
PCR and DNA assembly 
PCR products were amplified in 50 µL reactions containing: 1 µL homemade PfuX7 
DNA polymerase, 0.2 mM dNTPs (Thermo Scientific, Waltham, USA), 1 mM 
MgCl2, 1 mM DMSO, 0.5 µM forward oligonucleotide, 0.5 µM reverse 
oligonucleotide, Phusion® HF Reaction Buffer (New England BioLabs, Ipswich, 
USA) and 50 ng plasmid template. A touch-down PCR program was used for 
amplification: Step 1: 2 min 98°C; step 2:15 sec 98°C, 20 sec 65°C (-1°C per cycle), 
45 sec per kb at 72°C (step 2 repeated 9 times until 55°C, then repeated 20 cycles at 
the annealing temperature 55°C); step 3: 5 min 72°C; step 4 hold at 10°C. PCR 
products were gel purified using NucleoSpin Gel and PCR Clean-up (Macherey-
Nagel, Düren, Germany) and eluted in 10% TE buffer. A Nanodrop 
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spectrophotometer 2000 (Thermo Scientific, Waltham, USA) was used for estimation 
of PCR product and vector concentration. Purified PCR products were incubated with 
1 µL USERTM enzyme (New England BioLabs, Ipswich, USA) for 30 min at 37°C 
and subsequently mixed with linearized vector backbone. 3 µL of the assembled PCR 
product:vector solution was transformed into NEB 5-alpha chemically competent 
cells according to the manufacturer’s protocol. Transformants were selected on Luria 
Bertoni (LB) agar plates supplemented with 25 µg/mL kanamycin, 17 µg/mL 
chloramphenicol. Colonies were screened for gene insert by colony PCR using 
OneTaq 2X Master mix (New England BioLabs, Ipswich, USA). Vectors were 
extracted and purified using QIAprep Spin Kit (Qiagen) and verified by sequencing. 
Culture medium and expression conditions 
All experiments were performed with biological triplicates with BL21(DE3) as 
expression host. Overnight (ON) cultures in 96-deep well plates: 500 uL (DasherGFP 
variants BRCA1) or 800 uL (CYP720B4) terrific broth (TB) medium supplemented 
with 25 ug/mL kanamycin and 17 ug/mL chloramphenicol was inoculated with single 
colonies and grown overnight at 37oC (DasherGFP variants, BRCA1) or 30oC 
(CYP720B4), at 300 rpm in a 5cm orbital shaking incubator. ON cultures were 
diluted to a start OD600nm of 0.05 in fresh TB medium including antibiotics. The 
expression culture volume in 96-deep well plates was 500 uL (Dashers, BRCA1), in 
24-deep well plates it was 5 mL (CYP720B4); all grown to an OD600nm of 0.3-0.5. 
After induction with 2 mM L- rhamnose (DasherGFP variants) or 0.4 mM IPTG 
(BRCA1, CYP720B4), growth was continued for 4 hours at 37oC, 300 rpm 
(DasherGFP variants) or overnight at 25oC, 300 rpm (BRCA1) or 3 hours 25oC, 150 
rpm (CYP720B4).  
Whole cell fluorescence measurements 
Whole cell fluorescence was measured using 200 uL (Dashers and BRCA1) or 2 mL 
(CYP720B4) induced culture. CYP720B4 cultures were harvested (2,500xg, 20 min) 
and the pellets resuspended in a total volume of 100 µL PBS buffer. The GFP 
fluorophore was allowed to form for 2 h at room temperature (RT). The cultures 
harbouring the DasherGFP variantss or BRCA1 were measured directly after 
culturing. Fluorescence was detected by using excitation/emission wave length 
depending on the construct: 505nm/525nm for the DasherGFP variants, 
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580nm/610nm for BRCA1-mCherry and 485nm/512nm for CYP720B4-GFP with a 
window of +/- 9 nm, gain value 50 (CYP720B4) or 80 (BRCA1), using plate reader 
SynergyMx SMATLD (BioTek, Winooski, USA). 
SDS-page 
Cell pellets from 450 uL expression culture were resuspended in 20 mM Tris-HCL 
pH 8.0 including benzonase (0.5uL/mL) and adjusted to equal OD values. Cell lysis 
was done by freeze-thawing and the cell lysate was subsequently mixed 1:1 with 
SDS-sample buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 100 mM 
DTT, bromphenol blue) and boiled at 99 °C for 5 minutes. For SDS-PAGE, equal 
volumes of  cell lysate-sample buffer mixes were loaded and run in parallel with 
PageRuler™ Prestained Protein Ladder 10-170K (Thermo Scientific, Waltham, USA) 
on RunBlue 4-20% gradient SDS gels (Expedeon, USA) with RunBlue Rapid running 
buffer (Expedeon, USA) at 125 kV for 60 mins.  
Immunoblotting 
Proteins were transferred from SDS-PAGE onto nitrocellulose sheets (iBlot transfer 
stacks with Novex mini nitrocellulose membranes and iBlot Dry blotting 
system,,ThermoFischer Scientific, USA). Blocking was done ON at 4 °C with 5% 
(w/v) dried milk in TBS-T buffer, followed by 4x5mins washing with excessive TBS-
T volumes. Incubation with the 1° antibody (anti-T7 lysozyme from rabbit, 1:5000 
dilution) for 1 h at RT in TBS-T solution was followed by excessive washing with 
TBS-T, 1h incubation with 2° antibody (anti-rabbit from donkey, 1:2500 dilution) in 
TBS-T and again excessive washing. Detection was performed with Amersham ECL 
Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences, UK).  
RNA isolation 
1 mL samples in triplicates were harvested after 4h induction and snapfreezed at -80C 
after STOP solution (5% Phenol for RNA, 100% EtOH) treatment. Total RNA 
isolation was performed using Qiagen RNAeasy kit according to the manufacturers’ 
instructions. The protocol includes DNase treatment. 
RNA library preparation and sequencing 
The sequencing libraries were prepared in triplicates using a TruSeq RNA Stranded 
Sample Preparation kit (Illumina Inc., San Diego CA) and pooled together prior to 
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sequencing. An average cDNA library size was determined using the Agilent DNA 
1000 kit on an Agilent 2100 Bioanalyzer. Libraries were normalized and pooled in 10 
mM Tris-Cl, pH 8.0, plus 0.05% Tween 20 to the final concentration of 10 nM. 
Denaturated in 0.2N NaOH, 10 pm pool of 6 libraries in 600 ul ice-cold HT1 buffer 
was loaded onto the flow cell provided in the MiSeq Reagent kit v2 300 cycles and 
sequenced on a MiSeq® (Illumina Inc., San Diego CA) platform with a paired-end 
protocol and read lengths of 151 nt. On a regular basis, concentration and quality of 
the nucleic acids were determined by using a Qubit 2.0 fluorometer (Invitrogen) or an 
Agilent 2100 Bioanalyzer (Agilent Technologies). 
 
Analysis of RNA-sequencing data 
TopHat (2.1.0) and Cufflinks (2.2.1) suite was used for RNA-seq-based differential 
gene expression analysis as described by Trapnell, C. et al30. Reference genome and 
annotations for BL21(DE3) strain were retrieved from NCBI Reference Sequence 
Database (Version NC_012971.2). Features present on the pDR861-SR, pLysS and 
pRARE plasmids are added to reference manually. Sense and anti-sense read counts 
for tRNAs present on pRARE are determined using HTSeq library described by 
Anders, S. et al31 over reads mapped to plasmids alone. 
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Chapter 3 Assembly of highly standardized gene fragments for high-
level production of protoporphyrins in E. coli 
Assembly of highly standardized gene 
fragments for high-level production of 
porphyrins in E. coli 
 
 
 
Standardization of molecular cloning greatly facilitates advanced DNA engineering, 
parts sharing and collaborative efforts like the iGEM competition. All of these 
attributes facilitate exploitation of the wealth of genetic information made available 
by genome and RNA sequencing. Standardization also comes at the cost of reduced 
flexibility. We addressed this paradox by formulating a set of design principles aimed 
at maximizing standardization while maintaining high flexibility in choice of cloning 
technique and minimizing the impact of standard sequences. The design principles 
were applied to formulate a molecular cloning pipeline and iteratively assemble and 
optimize a six-gene pathway for protoporphyrin IX synthesis in Escherichia coli. 
State of the art production levels were achieved through two simple cycles of 
engineering and screening. The principles defined here are generally applicable and 
simplifies the experimental design of projects aimed at biosynthetic pathway 
construction or engineering. 
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3.1 Introduction 
The ability to recombine DNA with restriction enzymes and ligase moved molecular 
biology into a new era and was pivotal in the birth of biotechnology. More recently, 
whole genome sequencing has revolutionized molecular biology and paved the way 
for fields like metabolic engineering and synthetic biology. Exploitation of the 
unprecedented availability of sequence information seems now mainly limited by our 
ability to build, test and analyze variants of constructs, genes and pathways. 
Accordingly, a range of advanced methods for DNA cloning have recently emerged, 
addressing the more complex demands 1-5. Moreover, the need to standardize 
molecular cloning and share biological parts have been strongly emphasized 6. A 
prime example is the biobrick standard proposed by Tom Knight 7 that was followed 
by a parts sharing initiative heavily promoted by the iGEM synthetic biology 
competition. Several alternative biobrick formats and technologies have subsequently 
been described (BBF RFC process. 
http://openwetware.org/wiki/The_BioBricks_Foundation: RFC). However, the history 
of biobricks exposes two inherent complications in the pursuit of standardizing 
molecular cloning; 1) newly developed molecular cloning methodologies are not per 
se backward compatible, which compromises the benefits of part sharing and 2) 
standardization invariably results in addition of short sequences mediating the 
standardized DNA assembly. We decided to face these challenges, by formulating a 
set of design principles to guide the construction of a standardized DNA assembly 
pipeline. With the proposed design principles, the level of standardization is 
maximized while maintaining high flexibility in choice of cloning technique and 
minimizing the impact of standard sequences. The approach incorporates a substantial 
degree of variability and opportunities for custom design. As test case for our cloning 
pipeline, we selected production of protoporphyrin IX in Escherichia coli. 
Protoporphyrins have several properties that make them attractive as a model system; 
1) the red color of protoporphyrins allow for an easy optical assay, 2) the fluorescent 
properties of protoporphyrins allow specific and sensitive detection and relative 
quantitative comparison by HPLC, 3) Authentic standards are available for several 
protoporphyrins and 4) the enzymes involved in protoporphyrin biosynthesis are 
thoroughly characterized 8. Protoporphyrin IX is ubiquitously distributed in nature as 
a precursor in the synthesis of essential prosthetic tetraprotoporphyrin groups such as 
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in b- and c-type cytochromes, peroxidases, chlorophylls, cytochrome P450s and 
haemoglobins. Moreover, protoporphyrins, particularly the manganese containing 
ones, have application potential within the biomedical field as drug precursors and 
modulators of cancer cell growth 9.  
 
 
Figure 1. Activation of entry format fragments. The entry format is defined by the 9-bp single stranded 
overhang (sso) specified in the design principles. The 9-bp can be formed by a number of PCR and 
restriction enzyme based techniques. Panel a, Left: PCR based technique where uracils are incorporated in 
oligo nucleotides and sso’s are generated by enzymatic removal of the uracils after the PCR. The uracils 
mediating sso formation are highlighted in purple. Middle panel: TspRI restriction. Right panel: Combined 
type-II-S restriction endonuclease (here AjuI) and nicking endonuclease (here Nb.BtsI). A consequence of 
this approach is that the recognition sites for the nicking endonuclease are also translated resulting in 
addition of two amino acids on both sides of the ORF. The resulting entry fragments with processed sso’s 
are illustrated below. One base pair difference in the upstream and downstream sso’s ensures directional 
cloning (highlighted in red). The amino acids encoded by the 9 bp entry format sso are displayed below the 
nucleotide sequence. Panel b; illustration of the entry vector with entry-ORF inserted.  The entry vector 
adds a T7 promoter, a start codon, a stop codon and a T7 terminator to the cloned ORF (these elements are 
highlighted in pink, green, red and orange respectively). Panel c; results of T7 dependent 35S-methionine 
labeling of heme biosynthetic genes hemA-F . 
 
 Protoporphyrins are synthesized from glycine and succinyl-CoA through the 
Shemin pathway 10,11 or from tRNA loaded with Glutamate through the C5-pathway 
12-14.  d-Amino levulinic acid (ALA) is the first common intermediate in the two 
pathways.  E. coli naturally utilize the C5-pathway 15 and introduction of the Shemin 
pathway by heterologous expression of d-amino levulinic acid synthase (hemA) 16,17 
has previously been exploited to obtain high ALA titers 18. In this manuscript, we 
describe a standardized yet generic pipeline for DNA cloning and demonstrate its 
feasibility for pathway engineering by constructing a pair of plasmids that enable high 
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production of protoporphyrin IX (80 mM). The plasmids are selected through two 
engineering cycles based on screening of pathway variants, balancing expression of 
the six biosynthetic genes with semi-randomized Shine-Dalgarno (SD) sequences.  
3.2 Results and Discussion 
Design principles for cloning pipeline: 
The overall purpose of our cloning pipeline is to achieve streamlined, robust, high-
throughput cloning with a minimal requirement for de novo design. In addition, the 
pipeline design, and underlying principles, should be sufficiently generic to be 
compatible with a range of advanced cloning techniques. The major principles that we 
arrive at to fulfill these criteria is to standardize at two levels; 1) define an entry 
format and corresponding entry vector to achieve fully standardized incorporation of 
new DNA-parts and 2) design a general strategy for downstream parts assembly. The 
overall design principles that we arrive at for the entry format is that all entry-parts 
will be flanked by defined 9-bp sequences that facilitate directional ligase 
independent cloning with both PCR and restriction enzyme based technologies 
(Figure 1a). Specifically, the 9-bp flanking sequences are designed to contain 
recognition sequences for TspRI. TspRI is a unique restriction enzyme that generates 
a 9-bp single stranded overhang, thus providing a one step, error free method for 
activation prior to cloning (Figure 1a). The major advantage of this approach is that 
synthetic genes, free from internal TspRI sites, can be sub-cloned in a PCR-error-free 
manner.  The flexible entry format can also be created with simple PCR-based 
methods such as uracil-excision 19,20, enzyme free cloning 21 and PliCing 5. These 
methodologies will likely be useful when genes are cloned from the native source 
DNA. As a third alternative compatible entry fragments can be created using a 
methodology that resembles type-II-S restriction enzyme-based technologies such as 
MoClo 22 and Golden Gate 23. This third alternative relies on addition of internal 6-bp 
Nb. BtsI nicking enzyme recognition sites and is therefore ligase independent. Type-
II-S restriction enzyme-based technologies may be particular useful in robotics-based 
systems.  Homology/recombination-based cloning methodologies such as isothermal 
in vitro recombination 1, ligase independent cloning 24 or ligase cycling reaction 25 
could also be use the generate entry clones since these are highly flexible and 
sequence independent technologies.  The second principle is that protein coding 
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sequences are designed without start and stop codons. This ensures flexibility in terms 
of modifications such as addition of tags, linkers or fused gene constructs. A 
consequence of this is that the 9-bp sequences that facilitate cloning will be translated 
and could potentially interfere with protein function. To minimize this risk, the 
TspRI-containing 9-bp sequences are designed to encode only Serine, Threonine and 
Glycine. Serine and Glycine are the most commonly used residues in protein linker 
sequences 26 and Threonine only differ from Serine by one methyl group.   
Finally, we decided to utilize a T7-based expression vector as entry plasmid 
backbone. This introduces a simple quality checkpoint for proper translation of 
protein encoding entry fragments based on an assay for specific T7-dependent 
expression in the presence of rifampicin 27. In our case, we utilized a pET-DUET-1 
backbone as entry vector. The backbone was modified to position a start codon in 
optimal distance from a consensus SD sequence and immediately upstream of the 9-
bp entry sequence to ensure that no unwanted amino acids were included in the 
resulting protein. In principle any backbone can be prepared for hosting biobricks in 
this format by a plethora of techniques including PCR, TspRI or type-II-S restriction 
enzymes (Figure S1). 
Application of the standardized cloning pipeline to protoporphyrin IX production 
With the basic principles established we decided to utilize the cloning pipeline to 
explore aspects of pathway engineering in E. coli using protoporphyrin IX as test 
case.  We introduced the Shemin pathway in E. coli by heterologous expression of the 
model ALA synthase, hemA, from Rhodobacter capsulatus  as previously described 
18,28. The remaining enzymes required for protoporphyrin IX biosynthesis, encoded by 
hemB, hemC, hemD, hemE and hemF 8, were acquired from E. coli.  
 
Figure 2. Biosynthetic route for protoporphyrin IX by the Shemin pathway. Chemical structures of the 
expected products of hemD, uroprotoporphyrinogen III and hemF, protoporphyrin IX as well as the first 
dedicated intermediate d-aminolevulinic acid are displayed. 
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A schematic overview of the biosynthetic pathway is presented in Figure 2. All six 
genes were inserted in the pET-Duet-1 based entry vector as entry fragments by 
uracil-excision and transformed in E. coli BL21 DE3 for verification of transcription 
and translation by 35S-methionine labeling (Figure 1b). 
Indeed, translation of all six genes was confirmed. hemD appeared to be translated at 
a lower level indicating a possible bottleneck in pathway engineering (Figure 1c).  
Standardized assembly of multiple fragments. 
The next step in our pipeline construction was to standardize assembly of several 
fragments. Minimal de novo design, to avoid DNA assembly being the experimental 
bottleneck, and compatibility with multiple techniques and flexibility in terms of 
number of assembled fragments were the drivers for our design principles.  
Table 1. Generic linkers used for multi-fragment assembly 
Linker ID 
Sequence 
(sense) 
Complementary sequence 
(anti-sense) 
Length (bp) 
Entry fragment upstream ACCAGTGGT ACCACTGGT 9 
Entry fragment downstream AGCACTGGT ACCAGTGCT 9 
Generic linker A AGTCGGTGT ACACCGACT 9 
Generic linker B AAGCAGCGT ACGCTGCTT 9 
Generic linker C AGACGTCAT ATGACGTCT 9 
Generic linker D AGGTCTGAGT ACTCAGACCT 10 
 
At this stage, we focused on PCR based techniques as they allow highly flexible 
assembly of multiple fragments in a single cloning reaction 1,5,20. We arrived at the 
following simple design rules; 1) entry fragments should be PCR amplified 
exclusively by generic oligo nucleotides, which is possible due to the standardized 
entry formats allowing generic oligo nucleotides annealing in the common Gly-, Ser-, 
and Thr-encoding regions, and 2) linking regions that define specificity in multi-
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fragment assemblies should be designed with maximal sequence diversity and 
confined length (8-10bp) (Table 1). These principles allow generation of a very large 
number of assemblies using only a small set of benchmarked oligo nucleotides, thus 
minimizing de novo optimization and failed assemblies due to erroneous oligo 
nucleotides.  
 
Figure 3. Schematic overview of multi-fragment assembly from entry clones. Panel a; Illustration of entry 
clone (left) and backbone (right) amplification by generic oligo nucleotides. The three elements of the 
generic oligo nucleotides are depicted as follows; annealing part (green), control elements (blue upstream, 
purple downstream) and linker (white box). The five variants of the linker (A-D, Entry fragment (Ef)) are 
shown in extension of the oligo nucleotide. Sequences of the linkers are given in Table 1. Panel b + c; 
schematic overview of assembly process for four, b,  and two, c, entry fragments, respectively. Entry 
fragments R. capsulatus hemA (R.c.hemA), hemB, hemC and hemD were assembled into amplified pCDF-
Duet, whereas entry clones hemE and hemF were assembled into pET-Duet. Complementary linkers are 
illustrated with identical colors and letter codes. The semi-randomized SD sequence (rSD) was included in 
the upstream control element (C.E.) and the ptrc promoter downstream in all entry clones. Amplified 
backbones harbor a ptrc upstream and a T7 transcriptional terminator (tT7) downstream. The schematic 
overviews are not drawn to scale. 
 
 
The approach ensures backward compatibility as long as the linkers are maintained, 
making it straightforward to expand the assembly at a later stage. Moreover, the short 
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overlap sequences allow for incorporation of control elements (e.g. required for 
transcription and translation) while keeping the oligo nucleotides  
relatively short. This means that the gene expression levels can be tailored using 
permutations of the generic oligo nucleotides with e.g. variable promoters, SD-
sequences, leader sequences or peptide tags. In summary, generic oligo nucleotides 
contain three defined regions: An annealing part, a control element and an assembly 
linker (Figure 3a).  In contrast to the entry clone strategy, the described second-level 
multigene assembly strategy comes at the expense of flexibility in terms of cloning 
technology. 
 
Assembly of tetrapyrrole core biosynthesis genes 
The proof of concept pathway engineering was conducted as a screening study with 
constitutive promoters (ptrc) and diversity at the translational level mediated by semi-
randomized SD-sequences (NNNNNGGAN). The core GGA motif in the SD was 
fixed to reduce the occurrence of non-functional sequences as previously described 29. 
The semi-random SD was included as a control element in the upstream- and ptrc in 
the downstream-oligo nucleotide for the entry clone, while a ptrc and a transcriptional 
terminator was included as control elements in the backbone oligo nucleotides (Figure 
3a). Entry clones of R. capsulatus hemA, hemB, hemC and hemD were PCR amplified 
individually with the linker pairs A-B, B-C, C-D and D-Ec and assembled with a PCR 
amplified pCDF backbone harboring the Ec-A linkers (Figure 3b) and transformed 
into E. coli DH5a. 
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Figure 4. Protoporphyrin production in stage-one (hemA-D) clones. Panel a; colonies were screened by 
optical inspection directly on plates 72 h after transformation. Protoporphyrin producing clones were 
identified based on color intensity and 24 clones spanning the observed color intensity range were selected 
for analysis. Panel b; representative HPLC-FLD chromatogram of protoporphyrin producing clone (D1). 
The observed compounds are numbered 1,4 and 5. Panel c; representative mass spectra of protoporphyrin 
producing clone (D2). The panels show the dominant ions in each of the compounds 1,4 and 5 as well as an 
authentic standard (St) of protoporphyrin IX. Panel d; quantitative analysis of protoporphyrin production 
in 24 stage-one clones based on HPLC-FLD data. Each clone was analyzed in seven replicates and the 
graphs depict the average signal intensities with standard deviations. The upper panel summarizes the 
levels of 4 and 5 combined, as they could not be separated with the HPLC parameters used in this study. A 
general tetrapyrrole structure is embedded to illustrate that the exact structure of the compounds is 
unknown, but the fluorescence and mass spectrometrical data indicate a protoporphyrin class molecule. 
The lower panel depicts the protoporhyrin IX levels and the chemical structure of protoporphyrin IX 
(Pubchem) is embedded. 
 
The initial screen for protoporphyrin producing transformants was conducted directly 
on the LB-plate used for transformation. Simple optical inspection revealed highly 
diverse levels of protoporphyrin production among the transformants (Figure 4a). 
Approximately 10% of the colonies were intensely red-colored, 10% were white and 
the remaining had an intermediate color phenotype. Twenty-four E. coli colonies 
spanning the range of protoporphyrin producers were selected for further analysis. 
The pCDF-hemAD plasmids were purified and sequenced to establish the efficiency 
of the uracil-excision cloning and map the variance in SD-sequences.  
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The success rate of the cloning, defined as clones containing all four genes in correct 
order, was 79% (19 out of 24 clones as verified by sequencing).  
Table 2. Shine Dalgarno sequences from analyzed pCDF-hemA-D clones, their predicted RBS strengths and 
protoporphyrin production levels 
pCDF-hemA-D plasmids 
   
Predicted Shine-Dalgarno strength 
Protoporphyrin 
(sum of 
compound 4 
and 5) 
Clone 
ID hemA SD hemB SD hemC SD hemD SD 
hemA 
SD 
hemB 
SD 
hemC 
SD 
hemD 
SD 
 A1 GCATTGGAG TGTACGGAA TCTTTGGAT CTCCGGGAG 535 238 489 312 26906 
A2 GGTATGGAT GGTCCGGAT CCGGAGGAT TCATTGGAG 228 139 8514 586 3478 
A3 AATTCGGAG ATTTCGGAA n.d. CAATGGGAA 1507 586 125 511 3547 
A4 TGCCCGGAG GTGAGGGAT GCGTGGGAT CCGCCGGAT 641 229 2065 120 35769 
A5 GACATGGAT CGCGCGGAC ATTTTGGAG ACGTTGGAA 260 326 9452 51 4079 
A6 AAGGGGGAT AAGATGGAT GTGGTGGAT CCCTAGGAT 2526 103 1843 208 3447 
B1 GTGATGGAG GAGATGGAA ACCGCGGAG CGTTGGGAG 878 278 767 373 71167 
B2 TGGTCGGAC GGACTGGAG AGTACGGAT TTTTTGGAC 97 373 1440 373 3873 
B3 AAGAGGGAT - - - 518 
   
81363 
B4 ACCATGGAG GACTTGGAT ATGTTGGAT CGTTAGGAG 767 85 802 1440 160586 
B5 TCCTTGGAG GTTCGGGAT GTTCCGGAG TGAGTGGAA 1725 174 4600 670 104191 
B6 ATTGTGGAG TGGCAGGAG CGCTAGGAG GTTGGGGAT 918 560 2705 97 90191 
C1 GCTCAGGAT TGTTGGGAA CTGGAGGAT AGCCTGGAA 52 447 5429 228 4196 
C2 TTCGTGGAG CGTTGGGAG TCCTTGGAG CCCTAGGAG 1259 670 2160 2586 57429 
C3 CTCCAGGAT ACGTTGGAG TTGTAGGAT TGTGGGGAT 139 139 2065 116 148578 
C4 GGATTGGAT TCGGAGGAG GTGGTGGAG GATGTGGAT 238 1440 4642 14 4028 
C5 TTTTCGGAT TCATTGGAG __TCAGGAG TTGAGGGAT 260 373 6304 470 4009 
C6 CGAGCGGAT _CGCGGGAG ATCACGGAG TCCTTGGAT 50 918 2065 133 3191 
D1 GTTTTGGAG - - - 1051 
   
73002 
D2 TATTGGGAG AGACGGGAT GTGGGGGAT GAGTTGGAG 1772 285 13354 560 380934 
D3 GTAGGGGAA AGGGGGGAT TTTTTGGAT CCCGTGGAT 429 939 1576 139 13363 
D4 GTAGAGGAT - - - 802 
   
58055 
D5 - - - TAAGTGGAC 
   
312 7656 
D6 - - - GTCTCGGAC 
   
68 6492 
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The five remaining clones contained only one gene, which was either hemA (3 clones) 
or hemD (2 clones). This was not surprising, as these genes contain one linker with 
perfect match to the vector. The predicted strength of the 24 different combinations of 
SD-sequences were calculated using the The Ribosome Binding Site Calculator 30,31 
(Table 2), but no statistically significant correlations between predicted RBS strength 
and protoporphyrin levels were observed.  
 
Chemical characterization of stage-one clones 
All 24 selected E. coli colonies were subjected to detailed analyses by 
chromatography-based methods. HPLC coupled fluorescence detection (FLD) using 
excitation and emission wavelength selective for protoporphyrins (410nm 
excitation/620nm emission) revealed the presence of several signals (Figure 4b). 
Identification of the fluorescent compounds was attempted with Fourier transform 
mass spectrometry (FT-MS) analysis. The late eluding compound, 1, was identified as 
protoporphyrin IX based on both the retention time (1.6 min) and comparison with the 
mass spectra of an authentic standard (Figure 4c). The major signal obtained, 
however, turned out to contain two related co-eluding compounds 4 and 5 sharing an 
ion of 1169 m/z and with dominant ions of 577 and 631 m/z, respectively (Figure S2).  
Neither of these ions matches those derived from expected intermediates. The FT-MS 
analyses support that both 4 and 5 contain nitrogen and are capable of binding iron in 
the high molecular mass form (1169 m/z) and the FLD signal indicate a tetrapyrrole 
structure. Taken together with the exclusive co-occurrence of protoporphyrin IX with 
elevated levels of 4 and 5 (Figure 4d), this evidence suggests that 4 and 5 are indeed 
protoporphyrins. A metabolite with similar mass as 1 (557 m/z) has previously been 
observed in co-occurrence with protoporhyrin IX in E.coli constitutively expressing 
R. capsulatus hemA 32. The metabolite was identified as heme based on proposed 
signature ions, however, the accurate mass and isotope patterns available to us 
demonstrate that iron is not bound in the low molecular form (557 m/z), but 
exclusively in the high molecular form (1167 m/z) which rules heme out as a target. 
Previous studies identified uroprotoporphyrin I and III as the dominant species of 
protoporphyrins upon constitutive expression of R. capsulatus hemA with E. coli 
hemB, C and D 28. However, in our experiments, neither uroprotoporphyrin I nor III 
was detectable in any of the analyzed clones (data not shown). Absence of 
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uroprotoporphyrin III could be explained by insufficient hemD activity as the in vitro 
translation data suggested that hemD was not as efficiently expressed as the remaining 
genes.  The presence of unknown tetrapyrrols are therefore best explained by 
conversion of protoporphyrin intermediates into unknown derivatives and 
protoporphyrin IX by endogenous E. coli enzymes.  
Quantitative analysis of stage-one clones 
Based on the data from the HPLC-FLD analyses, we performed a relative 
quantification of the protoporphyrin producing capabilities of the clones in our 
collection (Figure 4d). Approximately half of the clones produced trace amounts of 4 
and 5 with no detectable protoporphyrin IX and are thus considered the background 
level. The remaining clones produced 4-53 fold more 4 and 5 than the background 
level while the protoporphyrin IX levels were fairly constant. The three clones 
containing only hemA (B3, D1 and D4) all produced protoporphyrin IX as well as 
decent amounts of 4 and 5 (Figure 4d), thus supporting previous observations that the 
initial step of heme biosynthesis indeed is limiting in E. coli 18. From a pathway 
engineering perspective, the clone D2 was by far the most promising as its ability to 
produce 4 and 5 was superior thus possibly offering a substantial gain in product 
formation upon re-engineering with the remaining pathway genes (Figure 4d). To 
verify that the protoporphyrin producing phenotype of clone D2 is indeed facilitated 
by the pCDF-hemA,B,C,D  plasmid, the purified plasmid was re-transformed into 
DH5a cells. Six clones were randomly chosen for analysis as described above. All six 
produced both protoporphyrins in similar levels as the original D2 clone thus 
confirming that the pCDF-hemA,B,C,D-D2 plasmid is responsible for this phenotype 
(data not shown).  
Building on stage-one clones for increased protoporphyrin IX production 
In a second engineering cycle entry fragments of hemE and hemF were amplified with 
matching generic oligo nucleotides (A-B, B-Ec), assembled with a pET-DUET 
backbone (Ec-A) and transformed into DH5α harboring pCDF-hemA,B,C,D-D2 
(Figure 3c). Again, transformants were selected based on color intensity and two 
superior clones c15 and c16 emerged from the subsequent HPLC-FLD screen.  
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Figure 5. Protoporphyrin IX production in stage-two (hemAD+hemEF) clones. Panel a; HPLC-FLD 
chromatograms of the parental stage-one clone (hemAD-D2, left) and the highest producer among the stage-
two clones, hemAD-D2, hemEF-c16 (middle) as well as mass spectrum of protoporphyrin IX produced in 
hemAD-D2, hemEF-c16. (right). Panel b absolute quantitation of protoporphyrin IX produced by stage-two 
clones at 16 OC (light gray) or 30 OC (dark gray). Bars display the average of three replicates and error bars 
denote the standard deviation. Panel c HPLC-FLD chromatograms from three stage-one clones re-
transformed with the high producing stage-two plasmid pET-hemEF-c15. Panel d absolute quantification of 
protoporphyrin IX produced by three stage-one clones re-transformed with either pET-hemEF-c15  (light 
gray) or pET-hemEF-c16 (dark gray) cultivated at 30 OC. Bars display the average of eight replicates and 
error bars denote the standard deviation. 
 
Both clones displayed a dramatic increase in protoporphyrin IX production 
accompanied by an equally dramatic decrease in the accumulation of 4 and 5, thus 
further supporting that 4 and 5 are intermediates in or derivatives of intermediates in 
protoporphyrin IX synthesis (Figure 5a). Absolute quantification of protoporphyrin 
IX by LC-FTMS revealed production capabilities ranging from 10-90uM 
corresponding to 6 to 50 mg/l (Figure 5b). Thus the best producing clones obtained 
(pCDF-hemAD-D2+pET-hemEF-c15 or C16) are within the same range as the 
highest producers previously reported (84+/-8 mM) 28. To further investigate the 
impact of the pET-hemE,F plasmids from c15 and c16 on protoporphyrin production, 
the plasmids were isolated, purified, sequenced and re-transformed into three stage-
one clones: an average producer (B6), a single gene hemA clone (D1) and the high 
producer (D2). In five of six combinations, transformation with pET-hemE,F resulted 
in increased levels of protoporphyrin IX and reduced accumulation of 4 and 5 (Figure 
5c-d). Curiously, the last combination (pCDF-hemAD-D2, pET-hemEF c16) resulted 
in clones that did not produce detectable levels of protoporphyrins as they did in the 
initial screen and in the identical replicate. To investigate whether this phenotype was 
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caused by alterations at the DNA level, pCDF-hemAD-D2 and pET-hemEF-c16 were 
isolated individually from a transformant randomly chosen among the analyzed 
colonies, and compared to the corresponding plasmid stocks by restriction analysis. 
Indeed, the pCDF-hemAD-D2 plasmid displayed an altered DNA fragment pattern, 
consistent with loss of R. capsulatus hemA, (Figure S3) and upon re-examination of 
the 24 stage-one clones we found several cases of instability over the prolonged 
incubation time of the assay. In the light of the induced plasmid instability observed 
in this study, and the previously obtained titers in the same range 28, it is tempting to 
speculate that production of protoporphyrins in the observed range is near the 
maximum that E. coli can tolerate. 
3.3 Concluding remarks 
In summary, we have demonstrated that by utilizing the cloning pipeline and design 
principles proposed in this manuscript, state of the art levels of protoporphyrin IX 
production (50 mg/l) can be achieved in E. coli through two simple design-build-test 
cycles. Moreover, the design allows not only maximizing production, but also 
generation of intermediary producers by alternative plasmid combinations. Although 
we do not obtain higher titers than previously shown 28 our work demonstrates that 
standardized genes and proteins (all six enzymes in the pathway contained the same 
linker sequences) can perform as well as the native versions. In addition to the 
example described here, we have recently successfully added the same peptide linkers 
to seven genes and proteins in a heterologous pathway for high-level production of a 
di-terpene in E. coli (Nielsen, MT and Nørholm, MHH, unpublished). The 
incorporated flexibility makes this approach useful for optimization of production 
scenarios as well as for rapid generation and iterative expansion of collections of 
clones with varying degrees of a defined phenotype.  In the simplified design used for 
our proof of principle studies, we introduced a risk for genetic instability by repeated 
use of the ptrc promoter. This may explain the observed occurrence of instable 
plasmids. For construction of stable production strains, this risk can trivially be 
eliminated by introducing different promoters as control elements in each set of 
generic oligo nucleotides. As the assembly of fragments relies exclusively on generic 
oligo nucleotides, part amplification can be heavily benchmarked and requires little 
de novo optimization. When combined with a robust cloning technique, such as the 
uracil excision cloning used in this manuscript (79% success rate with five DNA 
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fragments), screening based approaches become feasible and are readily 
accommodated in automated processes. Taken together, the simple design process, 
flexibility for fine-tuning by tailoring control elements in generic primers, reliable 
amplification and robust cloning, combined with the potential for automation, makes 
the pipeline a very useful tool for combinatorial assembly and optimization of 
biosynthetic pathways. 
3.4 Methods 
Strains and media 
Escherichia coli strain DH5α was used throughout this study unless otherwise stated. 
BL-21(DE3) was used for radioactive labeling studies. Bacteria were propagated on 
Luria-Bertoni (LB) agar plates supplemented with ampicillin (100mg/ml) or 
spectinomycin (50 mg/ml) where required. For liquid cultures, bacteria were 
propagated in 2xYT for plasmid purification, PASM media for 35S-methionine 
labeling and LB broth for protoporphyrin production assays. 
PCR and uracil-excision cloning 
Uracil-excision compatible PCR products were amplified with 28 cycles in 50 µl 
reaction mixtures using proof-reading PfuX7 polymerase33. USER Fusion was 
performed as previously described 20 with minor modifications. Uracil-excision 
cloning cassettes were designed following the principles described by 3. Uracil-
excision compatible vectors were generated by PCR as described by 34 using the 
settings outlined above or by restriction digest using the enzymes Fast Digest AjuI 
(Thermo Scientific) and Nb.BtsI (New England Biolabs). Purified PCR products of 
inserts and vector were mixed in a total insert to vector ratio of 6:1 (volume). When 
more than one insert is cloned simultaneously, equimolar amounts of each insert was 
maintained. The reaction mixture was buffered with 5x Phusion HF buffer 
(Invitrogen) and 1 U of USERTM enzyme mix (New England Biolabs) were added. 
The reaction mixture was incubated for 20 min at 37 °C, followed by 20 min at 25 °C 
before transformation of chemically competent E. coli cells. All primers used in this 
study are summarized in Table S1 
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Plasmid construction 
Compatible plasmid backbones were generated by inserting an NheI/PacI-digested 
AjuI-Nb.BsrDI cassette (GBlock, IDT-DNA, Table S1) into multiple cloning site-1 of 
pET-DUET (Novagen) using the XbaI and PacI restriction sites, generating pET-
MTSG-Aju,BsrDI. The start codon for translation is contained within the 5´Nb.BsrDI 
site, while a stop codon is positioned downstream of the 3´Nb.BsrDI site. Entry 
clones of hemB, E and F were PCR amplified from E. coli K-12 genomic DNA with 
primer sets designed to eliminate internal TspRI sites. Rhodobactor capsulatus hemA 
and E. coli hemC and D were synthesized as TspRI-free genes flanked by the entry 
sequence and activated by TspRI-digest. All entry clones were introduced into a PCR 
amplified pET-MTSG-AjuI-BsrDI vector by uracil excision cloning as previously 
described 3. Vector backbones for multi-gene assemblies were based on pCDF-DUET 
or pET-DUET (Novagen) and PCR amplified with uracil excision compatible 
primers. The primers were designed to introduce a trc-promoter and the A-linker 
upstream of the first insert as well as a T7-transcriptional terminator and the Db-linker 
downstream of the last insert. Entry clones for multi-gene assemblies were amplified 
with generic primers introducing a SD-sequence upstream and ptrc downstream. 
USER fusion assembly of entry clone inserts and backbones was essentially 
performed as previously described 20. Linkers were selected to match the backbone. 
All plasmids were validated by restriction digest patterns and sequencing. For a 
complete list of plasmids generated in this study consult Table S2. 
35S-labelling methionine labeling of proteins 
Transcription and translation of protoporphyrin biosynthetic enzymes flanked by the 
9bp entry sequence was confirmed by using the rifampicin blocking technique and 35S 
-labeling 35. Pre-cultures of BL21(DE3) cells carrying relevant plasmids were sub-
cultured (1:50) into 1 mL chemically defined rich medium lacking methionine 36. The 
cultures were grown at 37 0C to an optical density of 0.3-0.5, when expression was 
induced with 0.5 mM isopropyl-beta-D-1-thiogalactopyranoside. After 10 min of 
induction, the cells were treated with 25 mg/mL rifampicin for 10 min, labeled with 
15 uCi/ml 35S-methionine for 3 min, and harvested. The pellets were solubilized in 50 
uL lysis buffer (CellLytic B, 1 mM EDTA, 2 mM MgCl2, lysozyme, benzonase and 
complete protease inhibitor cocktail) and after 15 min incubation one volume of SDS-
PAGE sample buffer was added (125 mM Tris-HCl pH 6.8, 20% glycerol, 4 % SDS, 
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100 mM DTT, Bromphenol blue). Samples were applied on precast 4-20% SDS-
PAGE gels (Expedeon). Upon completion of the electrophoresis, the gels were dried 
and the labeled bands were visualized using a CyclonePus scanner (Perkin Elmer).  
 
Screening for protoporphyrin production 
Initial screening for protoporphyrin production was conducted directly from the plate 
used for transformation. Plates were incubated for 16 h at 37 0C after transformation 
to allow colony formation and then incubated for 72 h at 30 0C. At this stage, 
protoporphyrin production could be estimated by simple visual inspection due to red 
pigmentation accumulating in the colonies and the media. 
  
Assay conditions and extraction procedure 
For chromatographic assays, colonies were inoculated from plates into pre-cultures 
and grown 16 h at 37 0C and 300 rpm shaking. Assay cultures of 500ml fresh LB was 
inoculated with 10 ml pre-culture and grown in 2mL microtiter plates for 5 d at 30 0C, 
300 rpm or 4 h at 37 0C, 300 rpm followed by 5 d at 16 0C, 300 rpm shaking. All 
screening assays were made in seven replicates. Extracts for screening were processed 
as follows: cells were precipitated and supernatant discarded, pellet was re-suspended 
in 200 ml H2O and metabolites were extracted with 600 ml methanol at room 
temperature for 1 h. Cell debris was precipitated by centrifugation and cleared extract 
(600 ml) was acidified with 150 ml methanol pH 3.0, prior to analysis. For absolute 
quantification and compound identification we followed a procedure described by 
Kwon et al 28 with minor modifications. Absolute quantifications were made in 3 or 8 
replicates. Cells were grown in 2ml LB in 5ml microtiter plates for 5 d at 30 0C, 300 
rpm. Protoporphyrins exported to the media were precipitated with 4 mg/ml DEAE 
Sephadex A-25. Following precipitation, pellets were extracted twice with 2ml 
Acetone:Acetonitrile:Acetic Acid (10:1:0.1) at 40 0C with sonication. Extracts were 
cleared by centrifugation, evaporated to dryness and re-suspended in 1 ml methanol.  
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Analytical method 
Chromatographic separation of porhyrins was achieved using a five-minute isocratic 
method. Methanol adjusted to pH 3.0 with acetic acid was used as mobile phase and 
the column was an Ascentis Express Phenyl-Hexyl HPLC column (Supelco). 
Chromatographic separation was achieved on a Dionex UltiMate 3000 UHPLC. Flow 
0.4 ml/min, column oven at 30 0C. Fluorescence detection was made with a FLD-
3000 Fluorescence Detector (Thermo Fisher Scientific, San Jose, CA) and the data 
processed by the Chromeleon 7.1 Chromatography Data System (Thermo Fisher 
Scientific). Mass spectra were recorded by an Orbitrap Fusion Mass Spectrometer 
(Thermo Fisher Scientific, San Jose, CA) and data were processed with Xcalibur 3.0. 
Separation was achieved using the following parameters: Fluorescence detection 
parameters were 410nm for excitation and 620 nm emission. Mass spectrometry was 
performed in positive mode using electrospray ionization and full scan mode (350-
2000 m/z). The injection volume was 20 ml for HPLC-FLD analysis, 10 ml for 
HPLC-FT-MS.  
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Supporting Information 
Schematic examples of different backbone preparations, Fourier transform mass 
spectrometry (FT-MS) analysis of protoporphyrins and restriction analysis of selected 
stable and unstable clones. Material is available free of charge via the Internet at 
http:// pubs.acs.org.  
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Chapter 4 De-bugging and maximizing plant cytochrome P450 
production in Escherichia coli with a scalable GFP-based optimization 
scheme 
De-bugging and maximizing plant 
cytochrome P450 production in 
Escherichia coli with a scalable GFP-
based optimization scheme 
 
 
 
Cytochromes P450 are attractive enzyme targets in biotechnology as they catalyze 
stereospecific C-hydroxylations of complex core skeletons at positions that typically 
are difficult to access by chemical synthesis. Membrane bound CYPs are involved in 
nearly all plant pathways leading to the formation of high value compounds. In the 
present study, we systematically optimize the heterologous expression of six different 
plant-derived CYP genes in Escherichia coli, using a high-throughput workflow 
based on C-terminal fusions to the green fluorescent protein. The six genes can be 
over-expressed in a variety of E. coli strains using standard growth media. 
Furthermore, sequences encoding a small synthetic peptide and a small membrane 
anchor markedly enhance the expression of all six genes. For one of the CYPs, the 
length of the linker region between the predicted N-terminal transmembrane segment 
and the soluble domain is varied, verifying the importance of this region for 
enzymatic activity. The described work describes how membrane bound CYPs are 
optimally produced in E. coli and thus adds this plant multi-membered key enzyme 
family to the toolbox for bacterial cell factory design. 
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4.1 Introduction 
Escherichia coli is a model organism and a popular workhorse for protein production, 
with a comprehensive set of available genetic tools. An obvious extension to 
producing individual proteins for downstream applications is to produce a set of 
enzymes that catalyze an entire biosynthetic pathway. In our desire to advance from a 
petrochemical based society towards a bio-based society, it is critical that we deepen 
our understanding of how such heterologous biosynthetic pathways should be 
designed and maintained for the production of high value chemicals from renewable 
feedstock (Møller, 2014). Plant cytochrome P450 enzymes (CYPs) are central to this 
approach, as they are involved in nearly all pathways that lead to the formation of 
high value compounds such as terpenoids, alkaloids and phenylpropanoids (e.g. 
flavonoids, isoflavonoids, chalcones, aurones and lignans). Many of these compounds 
are used as medicines, condiments, flavors and fragrances (Morant et al., 2003), with 
well known examples being the antimalarial diterpenoid artemisinin (Chang et al., 
2007), the anti-cancer drug paclitaxel (Chau et al., 2004), the flavor compound 
vanillin (Gallage and Møller, 2015; Hansen et al., 2009) and the steviol glucoside 
based-sweeteners (Davies and Deroles, 2014). Typically, the membrane anchored 
CYPs catalyze stereospecific hydroxylations of complex core carbon skeletons, at 
positions that are difficult to access by de novo chemical synthesis. CYPs often show 
high substrate specificity and although members of this ancient multigene family are 
found in all domains of life, plants seem to be particularly enriched with often more 
than 250 CYPs in a single species (Nelson, Biochim Biophys Acta (2011) 1814: 14-
18). Unfortunately, plant CYPs have the reputation of being notoriously difficult to 
produce in E. coli (Chang et al., 2007). Furthermore, in order to work efficiently, 
CYPs often need co-production of other membrane-associated proteins such as 
reductases (Eugster et al., 1992) or cytochromes b5 (Paddon et al., 2013; Zhang et al., 
2007). 
Previous approaches to improve plant CYP production in E. coli includes 
exchanging parts of the native amino-terminal region with parts of the amino-terminal 
region of a codon optimized bovine CYP17alpha; often referred to as the “Barnes 
sequence” (Bak et al., 1998a; 1997; Barnes et al., 1991; Leonard and Koffas, 2007). 
Similarly, bacterial expression of human CYPs have been aided by bacterial leader 
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sequences such as the membrane translocation signals from pelB and ompA (Pritchard 
et al., 1997); for a recent review see (Zelasko et al., 2013) 
Membrane protein production in E. coli has benefited greatly from the 
introduction of a streamlined green fluorescent protein-based pipeline for rapid and 
simple assessment of proper expression (Drew et al., 2006; 2005; 2001; Lee et al., 
2014). Briefly, a carboxy-terminal GFP-fusion has many advantages: without 
interfering with membrane targeting and integration, it acts as an expression reporter 
as fluorescence indicates that the mRNA was translated in full. Importantly, if the 
upstream protein is mislocalized and subsequently aggregated, GFP fluorescence is 
completely quenched. Further, once folded, GFP remains fluorescent even during 
otherwise denaturing applications such as SDS-PAGE. In summary, the carboxy-
terminal GFP provides a cheap, reliable and fast readout of the proper production of 
membrane proteins. Moreover, the fluorescent properties of such chimeric proteins 
can be used for screening the optimal solubilization conditions for downstream 
applications, such as structural studies (Kawate and Gouaux, 2006; Sonoda et al., 
2011).  
Currently, there is no established formula for the heterologous expression of 
CYPs in E. coli. The literature is scattered with a wealth of different genetic 
manipulations and use of various strains and growth conditions. To enable efficient 
heterologous CYP production, there is an obvious need to systematically determine 
proper and generally useful expression conditions. Here, we demonstrate how 
functional expression of six different plant CYPs in E. coli is achieved by very simple 
means. The carboxy-terminal GFP-approach readily lends itself to high throughput 
applications, and therefore the proposed setup is bound to be highly useful for large 
scale expression screens.  
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4.2 Materials and Methods 
Bacterial strains 
Escherichia coli strain NEB 5-alpha (New England BioLabs, Ipswich, USA) was used 
for cloning of PCR products and propagation of plasmids. The following E. coli 
strains were used for gene expression: Rosetta2(DE3) pLysS (Novagen, Merck 
Millipore, Germany), Bl21(DE3) pLysS (Promega, Madison, USA), C41(DE3) 
(Miroux and Walker, 1996), KRX (Promega, Madison, USA), MC4100(DE3)pLysS 
and MG1655(DE3)pLysS.  
 
PCR and uracil excision 
All DNA manipulations were performed using uracil excision technology as 
previously described (Nour-Eldin et al., 2006; Nørholm, 2010) and all 
oligonucleotides are listed in Table S1. PCR products were amplified in 50 µL 
reactions containing: 1 µL PfuX7 DNA polymerase, 0.2 mM dNTPs (Thermo 
Scientific, Waltham, USA), 1.5 mM MgCl2, 0.5 µM forward oligonucleotide, 0.5 µM 
reverse oligonucleotide, Phusion® HF Reaction Buffer (New England BioLabs, 
Ipswich, USA) and 50 ng plasmid template. A touch-down PCR program was used 
for amplification: Step 1: 2 min 98°C; step 2:15 sec 98°C, 20 sec 65°C (-1°C per 
cycle), 45 sec per kb at 72°C (step 2 repeated 9 times until 55°C, then repeated 20 
cycles at the annealing temperature 55°C); step 3: 5 min 72°C; step 4 hold at 10°C. 
PCR products were gel purified from 1% (w/V) agarose gel using NucleoSpin Gel 
and PCR Clean-up (Macherey-Nagel, Düren, Germany) and eluted in 10% TE buffer. 
Purified PCR products were incubated with 1 µL USERTM enzyme (New England 
BioLabs, Ipswich, USA) for 30 min at 37°C and subsequently mixed with linearized 
vector backbone in a molar ratio 3:1 and incubated at 18°C for 1 h. A Nanodrop 
spectrophotometer 2000 (Thermo Scientific, Waltham, USA) was used for estimation 
of PCR product and vector concentration. Approx. 5 µL of the assembled PCR 
product:vector solution was transformed into NEB 5-alpha chemically competent 
cells according to the manufacturer’s protocol. Transformants were selected on Luria 
Bertoni (LB) agar plates supplemented with 50 µg/mL kanamycin, 25 µg/mL 
chloramphenicol or 10 µg/mL gentamycin.  Colonies were screened for gene insert by 
colony PCR using OneTaq 2X Master mix (New England BioLabs, Ipswich, USA). 
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Vectors were extracted and purified using QIAprep Spin Kit (Qiagen) and verified by 
DNA sequencing (Eurofins Genomics, Ebersberg, Germany ).  
DNA constructs 
All DNA constructs were made with uracil excision as previously described (Nour-
Eldin et al., 2006; Nørholm, 2010). Details of oligonucleotides, template DNA and 
references can be found in Tables S1 and S2 and below. Briefly, AsiSI restriction 
enzyme recognition sites, present in the kanamycin resistance cassettes, were deleted 
from all pET28a(+)-derived construct . AsiSI uracil excision compatible cloning 
cassettes were inserted between sequences encoding a TEV protease site, GFP and 
polyhistidine tag and either the 28-tag (Nørholm et al., 2013) (Fig. 1A), a Barnes-like 
N-terminal sequence MALLLAVF, SohB (residues 1-48, KDT39511) or YafU 
(residues 1-88, KEN61237) . Six genes encoding different plant CYPs (Sorghum 
bicolor CYP51G1 (U74319); Avena strigosa CYP51H10 (DQ680849); Sorghum 
bicolor CYP71E1 (O48958); Sorghum bicolor CYP79A1 (U32624); Arabidopsis 
thaliana CYP79B2 (NM_120158) and Picea sitchensis CYP720B4 (HM245403)) 
were PCR amplified with sequence specific oligonucleotides and cloned into the 
different pET28-derived vectors either treated with the restriction enzyme AsiSI 
(Thermo Scientific, Waltham, USA) and the nicking enzyme Nb.BbvCI (New 
England Biolabs, Ipswich, USA) or PCR amplified. The sohB- and yafU-based E. coli 
membrane anchors have their C-termini on the cytoplasmic side of the E. coli inner 
membrane (Daley et al., 2005) and therefore the plant CYPs cloned into the 
corresponding backbones had their predicted N-terminal anchors truncated to avoid 
translocation of the CYP into the periplasmic space. Truncations were designed using 
TMHMM v. 2.0 (Sonnhammer et al., 1998). A Strep-HRV3C tagged, codon 
optimized Sorghum bicolor CPR2b (Wadsäter et al., 2012) was cloned into 
pET28a(+)-tev-gfp-his8 and gfp was subsequently deleted and the origin of replication 
was swapped with the corresponding parts from pSEVA63 (Silva-Rocha et al., 2013) 
by amplifying pSEVA63 with the oligo nucleotides 5´-
ATCCGCTUTAATTAAAGGCATCAAATAAAAC-3’ and 5´-
ACTAGTCTUGGACTCCTGTTGATAGATC-3’ and the pET28-based cpr2b 
construct with the oligo nucleotides 5´-
AAGCGGAUCTACGAGTTGCATGATAAAGAAGACAGTC-3’ and  5´-
AAGACTAGUCAATCCGGATATAGTTCCTCCTTTCAG-3’. A truncated version 
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of E. coli lepB was amplified from a previously described pGem1-Lep construct 
(Hessa et al., 2005) using the oligonucleotides 5´-
ACTCGAGGAUGGCGAATATGTTTGCCCTGATTC-3’ and 5´-
ATCGCTGCUTCCAGGACCACCACTAGTCTCG-3’ and combined with the 
pET28-based full length CYP constructs amplified with 5´-
ATCCTCGAGUCTCCTTCTTAAAG-3’ in combination with the gene specific 
forward oligo nucleotides. 
 
Culture media and expression conditions 
All strains were grown aerobically in liquid cultures. For plasmid propagation single 
colonies were grown over night in 2xYeast/Tryptone medium at 37°C 250 rpm. For 
single plasmid transformations, chemically competent cells were transformed with 20 
ng plasmid according to the manufacturer’s protocol. For co-transformation of 
plasmids for expression assays, electrocompetent cells were transformed with 20 ng 
of plasmid DNA.  Four different media were tested for expression, LB (1% tryptone; 
0.5% yeast extract; 1% NaCl),  Terrific Broth (TB) (1.2% tryptone; 2.4% yeast 
extract; 0.4% glycerol; 17 mM potassium phosphate (monobasic); 72 mM potassium 
phosphate (dibasic)); the defined rich medium PA-5052 (Studier, 2005) (50 mM 
Na2HPO4; 50 mM KH2PO4; 25 mM (NH4) 2SO4; 2 mM MgSO4; 10 µM metals; 0.5% 
glycerol; 0.05% glucose; 0.2% alpha-lactose; 200 µg/mL amino acids E, D, K, R, H, 
A, P, G, T, S, Q, N, V, L, I, F, W and M). and minimal M9 (M9 salts; 2mM MgSO4; 
0.1mM CaCl2; 0.2% glycerol; 0.2% glucose; 10 µM Fe3+; 200 µg/mL amino acids E, 
D, K, R, H, A, P, G, T, S, Q, N, V, L, I, F, W and M). For media tests, over night 
cultures were prepared with each of the four media supplemented with 0.5% (w/V) D-
glucose and appropriate antibiotics. The pre-cultures were subsequently inoculated 
into each of the corresponding media for expression. For other expression assays, 
over night cultures were made in 96 deep well plates, inoculating single colonies into 
800 µL TB supplemented with 0.5% (w/V) D-glucose and appropriate antibiotics and 
grown at 30°C 250 rpm in Innova®44R incubator shaker system (5 cm orbital 
shaking) (New Brunswick Scientific, Eppendorf, USA).  The optical density (OD) of 
the over night cultures was measured at Abs600nm on Plate Reader SynergyMx 
(SMATLD) (BioTek, Winooski, USA). Over night cultures were inoculated into 5 
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mL fresh TB medium in 24 deep well plates to a final OD of 0.05. Cells were 
incubated for approx. 2 h at 37°C 250 rpm to an OD of 0.3-0.5. All strains were 
induced with a final conc. of 0.4 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG, 
dioxane free, Thermo Scientific, Waltham, USA). Despite the autoinduction capacity 
of the PA-5052 medium, as described previously (Lee et al., 2014), IPTG was use for 
induction in this medium as well.  The strain KRX was furthermore induced with a 
final conc. of 5 mM L-rhamnose (Sigma-Aldrich, St. Louis, USA). Cultures were 
subsequently incubated at 25°C 150 rpm for 3 h or 22 h.  
 
Whole cell fluorescence measurements 
Whole cell fluorescence was measured using 2 mL induced culture. The cells were 
harvested (2,500xg, 20 min) and resuspended in a total of 100 µL PBS buffer. The 
GFP fluorophore was allowed to form for 1 h at room temperature and then 
fluorescence was detected using excitation at 485nm and emission at 512nm with a 
window of +/- 9 nm, gain value 50, using plate reader SynergyMx SMATLD 
(BioTek, Winooski, USA). 
 
SDS-PAGE  
Whole cells were lysed for 1.5 h at room temperature in TRIS buffer (50 mM Tris 
HCl pH 7.5; 150 mM NaCl; 2 mM MgCl2) with 250 U/mL Benzonase ® nuclease 
(Sigma-Aldrich, St. Louis, USA); 5 mg/mL lysozyme egg white powder (Amresco, 
US, Ohio) and the cOmplete ULTRA EDTA-free protease inhibitor cocktail (Roche, 
Basel, Switzerland). The cell lysate (OD600nm0.1) was analyzed in parallel with 
PageRuler™ Prestained Protein Ladder 10-170K (Thermo Scientific, Waltham, USA) 
by standard SDS-page using Mini-PROTEAN® TGXTM 4-15% gels (Bio-Rad, 
Hercules, USA). In-gel fluorescence was detected on a G:BOX UV-table (Syngene, 
Cambridge, UK).  
 
Enzyme activity measurements 
For CYP79A1 enzymatic assays, cells were harvested by centrifugation 2,500xg 4°C 
for 10 min, washed once in 50 mM Potassium phosphate (KPi) buffer pH 7.5 and 
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resuspended to 0.03 OD units per µL in 50 mM KPi buffer. The enzyme reaction was 
carried out in 30 µL volume consisting of 5 mM NADPH, 0.5 mM L-Tyrosine 
(Sigma-Aldrich, St. Louis, USA), 50 mM KPi buffer and 20 µL cell suspension. Cells 
were incubated at 30°C 400 rpm for 60 min. The product (E)-p-
hydroxyphenylacetaldoxime (oxime) was extracted by adding 150 µL methanol 
followed by incubation at room temperature for 10 min. Cells debris was discarded 
twice by centrifugation (20,000xg, 10 min) and the supernatant was transferred into 
HPLC vials and stored at -20°C prior to analysis. The oxime was also extracted 
directly from cultures co-expressing SbCYP79A1 and SbCPR2b. 100 µL culture was 
extracted with 100 µL methanol, as described above. 
 
LCMS detection  
The CYP79A1 product (E)-p-hydroxyphenylacetaldoxime (Mw 151.17) was detected 
and quantified by LC-MS. A chemically synthesized (Z)-p-
hydroxyphenylacetaldoxime standard was kindly provided by Mohammed Saddik 
Motawie (University of Copenhagen, Department of Plant and Environmental 
Sciences). The two geometrical isomers (Z)-p-hydroxyphenylacetaldoxime and (E)-p-
hydroxyphenylacetaldoxmie were detected in both the chemical oxime standard and 
the oxime sample product due to instability and chemical equilibrium. Thus for the 
purpose of total oxime quantification the chromatogram area of the both peaks were 
summed. LC-MS data was collected on a Bruker Evoq triple quadropole mass 
spectrometer equipped with an Advance UHPLC pumping system. Samples were held 
in the CTC PAL autosampler at a temperature of 10.0 °C during the analysis. 
Injections (2 µL) of the sample were made onto a Supellco Discovery HS F5-3 HPLC 
column (3 µm particle size, 2.1 mm i.d. and 150 mm long). The column was held at a 
temperature of 30.0 °C. The solvent system (flow rate: 1.0 ml/min) used was water 
with (A) 100mM ammonium formate and (B) acetonitrile using the following elution 
profile: 0.5 min 95% A/5% B, linear gradient to 50% A/50% B for 3.0 min, 1.5 min 
50% A/50% B and re-equilibration for 2 min 95% A/5% B. The column eluent flowed 
directly into the heated ESI probe of the MS, which was held at 350°C and a voltage 
of 4500 V. SRM data was collected in centroid at unit mass resolution. Positive ion 
mode with Q1 set to monitor 152.70 m/z, Q3 set to monitor 136 m/z and Q2 set to a 
collision energy of 10.0eV, with an Argon pressure of 1.5 mTorr. The other MS 
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settings were as follows, Sheath Gas Flow Rate of 40 units, Aux Gas Flow Rate of 40 
units, Sweep Gas Flow Rate of 20 units, Ion Transfer Tube Temp was 350 °C. 
 
4.3 Results 
Full length expression of six plant CYPs in E. coli grown in standard media 
Previously, it was shown that simple addition of a 84 nucleotide/28 amino acid tag 
(28-tag) to the amino-terminus greatly enhanced the expression of challenging 
membrane protein encoding genes in E. coli (Nørholm et al., 2013). Here, we used a 
similar design principle to sandwich plant CYPs between an amino-terminal 28-tag 
and a carboxyterminal GFP (Fig. 1A). Six CYP genes from four different mono- and 
dicotyledonous plants were cloned into the pET28-28tag-tev-gfp-his8 plasmid: 
Sorghum bicolor CYP51G1 (Bak et al., 1997),CYP71E1 (Bak et al., 1998a) and 
CYP79A1 (Koch et al., 1995), Avena strigosa CYP51H10 (Qi et al., 2006), 
Arabidopsis thaliana CYP79B2 (Bak et al., 1998b); and Picea sitchensis CYP720B4 
(Hamberger et al., 2011) and transformed into E. coli KRX. Following three hours 
induction in four different standard growth media (LB, TB, M9 supplemented with 
Fe3+ and the synthetic rich medium PA-5052); expression and protein integrity was 
analyzed by measuring whole cell- and in-gel fluorescence. Compared to an empty 
vector control, all six constructs exhibited significantly elevated fluorescence levels in 
all growth media except M9 (Fig. 1B). Moreover, analysis of the samples by in-gel 
fluorescence indicated that the majority of the constructs were expressed as full-
length proteins (Fig. 1C), except for CYP51H10 for which a significant proportion 
seemed to be truncated or partly degraded. Addition of 5-aminolevulinic acid, 
suggested to aid the functional production of heme-containing proteins (Sudhamsu et 
al., 2010) did not have any apparent effect on expression levels (data not shown). 
Based on the highest expression level and cell density, we chose TB medium for 
further expression optimization.  
Chapter 4 
 89 
 
Figure 1. Production of six different CYP enzymes in standard growth media. (A) Schematic representation 
of the cloning procedure used. Genes encoding six different CYPs were PCR amplified with specific uracil-
containing tailed oligonucleotides and assembled with a compatible AsisI/Nb. NbvcI treated vector. (B) 
Effect of media on production of CYP51G1, CYP51H10, CYP71E1, CYP79A1, CYP79B2 and CYP720B4 in 
the KRX strain. Four media types were tested: Luria Bertoni (LB), Terrific Broth (TB), minimal media M9 
and autoinducing media (AI). As cell cultures reached the exponential growth phase, cultures were induced 
for 3 h. Cell cultures were subsequently harvested by centrifugation and resuspended in PBS buffer for 
whole cell fluorescence detection (relative fluorescence unit (RFU) per optical density (OD)). Error bars 
indicate standard error of the mean (n=3). Empty vector (control) was included as reference. (C) The level 
of full-length GFP-fused protein monitored from cell lysate by in-gel fluorescence detection. 
 
E. coli strains KRX and Rosetta excel in plant CYP expression 
Next we compared expression levels of the six different CYP constructs in the six 
different E. coli strains MC4100(DE3) pLysS, MG1655(DE3) pLysS, KRX, 
BL21(DE3) pLysS, Rosetta2(DE3) pLysS , and C41(DE3). In all strains except for 
KRX and C41, expression from the T7 promoter is catalyzed by the T7-phage derived 
RNA polymerase controlled by the PlacUV5 IPTG-inducible promoter. In three of the 
strains, potential toxic effects of over-expression is counteracted by expression of the 
natural T7 DNA polymerase inhibitor T7 lysozyme from the pLysS or the pRARE 
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plasmid (Studier, 1991), whereas a similar effect is obtained in C41 by mutations in 
PlacUV5 that make the promoter less strong (Wagner et al., 2008). In the commercial 
strain KRX expression of T7 RNA polymerase is tightly controlled by a rhamnose 
inducible promoter.  
 
Figure 2. Strain-dependent production of CYP enzymes. (A) Three K-strains (KRX, MC4100pLysS, 
MG1655pLysS) and three B-strains (C41, Bl21pLysS, Rosetta2pLysS) were transformed with 28-
tag:CYP:tev-gfp-his8 expression constructs.  Cells were grown in TB media and induced for 3 h, as cell 
cultures reached the exponential growing phase. Overall expression was monitored by whole cell 
fluorescence detection (relative fluorescence unit (RFU) per optical density (OD)). Error bars indicate 
standard error of the mean (n=3). Empty expression vector was included as control. (B) The level of full-
length GFP-fused protein was monitored from cell lysate by in-gel fluorescence detection in the three B-
strains (left panel) and the three K-strains (right panel). 
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The six pET28-28tag-CYP-tev-gfp-his8 constructs were transformed into the six 
different strains and expression was monitored by whole cell- (Fig. 2A) and in-gel- 
(Fig. 2B) fluorescence after 3 h induction. As judged from whole cell fluorescence 
and presence of full-length protein on SDS-gels, strains KRX and Rosetta2(DE3) 
pLysS clearly outperformed the other four strains (Fig. 2A and 2B). 
 
A transmembrane domain encoded by E. coli sohB normalizes expression of plant 
CYP genes to high levels 
Most eukaryotic CYPs utilize N-terminal hydrophobic peptides to localize to the 
endoplasmic reticulum, and sequence modifications in this region have previously 
proven essential for heterologous expression (Barnes et al., 1991). We hypothesized 
that it would be beneficial to exchange the plant ER/membrane localization signals 
from the CYPs with membrane anchors that are derived from the heterologous 
expression host and that have previously been shown to express at high levels from 
the T7 promoter. To find suitable candidates, we mined a previously published library 
of membrane protein encoding genes expressed in E. coli (Daley et al., 2005). We 
chose three of the most highly expressed genes (Fig. 1S.) that encoded membrane 
proteins with different topologies: sohB, encoding a single-pass membrane protein 
with the C-terminal end localized inside the bacterial cytoplasm (Cin), yafU, encoding 
two membrane spanning regions with a Cin topology; and lepB, encoding two 
membrane spanning regions, but with the opposite (Nout) topology (Fig. 3A). To 
mimic the overall topology of the microsomal plant CYPs and ensure localization of 
the CYP catalytic domain to the cytoplasm, we replaced the hydrophobic sequences 
of the CYPs with the transmembrane parts of SohB and YafU; whereas the full length 
CYP was fused to the periplasmic carboxy-terminus of LepB. For benchmarking 
purposes, we added a Barnes-like MALLAVF-encoding sequence to the six CYP 
genes and comparisons were made to unmodified plant CYP sequences. The native 
controls, 28-tag-, MALLAVF-, sohB-, yafU- and lepB-tagged CYP constructs were 
transformed into KRX and Rosetta2(DE3) pLysS and expression was monitored by 
whole cell (Fig. S2) and in-gel fluorescence (Fig. 3B). None of the native N-
terminally unmodified sequences expressed to any significant levels. In contrast, both 
the 28-tag and the SohB-domain normalized the expression of the CYPs to high levels 
and in particular the combination of the KRX strain with the SohB-tagged CYPs 
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consistently gave high levels of full-length protein. Furthermore, compared to the 28-
tag constructs, a higher proportion of SohB-tagged CYP79A appeared as full-length, 
both 3 h and 22 h-post-induction (Fig. S3) 
 
Figure 3. Effect of different N-terminal peptides and small bacterial membrane anchors on the expression of 
six different CYPs. (A) Illustration of the hypothetical membrane topology of native CYPs and recombinant 
bacterial anchor constructs: (from left) reference CYP with native N-terminal sequence, SohB membrane 
domain (1TM, highlighted in red) fused with a truncated CYP, YafU anchor (2TM, Cin, highlighted in 
orange) fused with a truncated CYP, and LepB anchor (2TM, Cout, highlighted in yellow) fused to a native 
CYP. All constructs have TEV:GFP:His8 fusions at their C-terminal. (B) Six CYPs were tested with 
different N-terminal modifications: (from left) native sequence as reference, 28-tag fused to native CYP 
sequence, Barnes–like MALLAVF peptide fused to native CYP sequence, SohB membrane domain fused to 
a truncated CYP sequence, YafU membrane domain fused to a truncated CYP sequence and the LepB 
membrane domain fused to a native sequence. Constructs were expressed in two strains (KRX and 
Rosetta2(DE3)pLysS). Cell cultures were induced for 3 h before harvest. Cell lysates were analysed by in-
gel fluorescence to determine the level of full-length protein present. 
 
Activity is preserved in all engineered versions of CYP79A1 except for those 
truncated in a proline rich region that precedes the soluble catalytic domain 
To obtain detectable expression levels of CYPs, we substantially re-engineered plant 
CYP proteins with truncations and/or heterologous protein domains such as the five 
different amino-terminal peptides and the large carboxy-terminal GFP domain 
described above. To test that a CYP is able to retain activity with these major 
modifications, we functionally assayed all the modified versions of CYP79A1 both in 
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vivo and in vitro while monitoring expression levels by fluorescence. Moreover, we 
checked the effect of truncating CYP79A1 at the residue Y36, likely placed at the 
interface between the membrane and the aqueous face; at the residue P69, placed at a 
proline-rich, proposed hinge region observed in many P450s (Chen et al., 1998; 
Leonard and Koffas, 2007; Williams et al., 2000); and at two positions in between 
these two extremes (P44 and P60, Fig. 4A).  
 
Figure 4. Functional assaying of engineered variants of CYP79A1. (A) Schematic overview of CYP79A1 
modified expression constructs used in this study. Four truncated expression constructs were designed to 
remove various parts of the N-terminal sequence: Δ1-35: at the end of the predicted transmembrane 
segment between residues 1 and 35, and at three proline residues at positions 44, 60 and 70 (Δ1-43, Δ1-59, 
Δ1-69) preceding the catalytic domain. In addition, an artificially extended linker region was engineered by 
inserting a repeat of the amino acids Y36-P44. (B) CYP79A1-catalyzed conversion of L-Tyrosine to (E)-p-
hydroxyphenylacetaldoxime. (C) Differently truncated and engineered CYP79A1 constructs were co-
produced with the compatible reductase electron donor CPR2b in the KRX strain. Cells were induced for 
22 h, before oxime was extracted from the culture. Empty vector control and 28-tag:native CYP79A1 
expressed without CPR were included as references. Error bars indicate standard error of the mean (n=3). 
 
In the in vitro assay, CYP79A1 and the reductase Sorghum bicolor CPR2b were co-
expressed in the KRX strain and the activity was measured on harvested cells by 
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adding NADPH and the substrate tyrosine. Formation of the product (E)-p-
hydroxyphenylacetaldoxime (Fig. 4B) was followed by separation using high 
performance liquid chromatography and mass detection (LCMS) Fig.S4 and S5A). In 
parallel, we performed a quantitative in vivo assay by co-expressing CYP79A1 with 
SbCPR2b and monitoring oxime formation with LCMS detection (Fig. 4C). Whole 
cell fluorescence confirmed expression of all constructs except the construct with the 
native, unmodified CYP79A1 sequence, as described above (Fig. S5B), and most of 
the expressed constructs were catalytically active except for those with the most 
heavily truncated CYP79A1 sequence at position P69. Cells expressing the YafU and 
LepB fusions were less active than those expressing the 28- and the SohB-fusions 
(Fig. 4B). In order to see if the distance to the membrane is important, we increased 
the linker between the membrane anchor and the soluble domain by duplicating the 
sequence Y36-P44 in the SohB-CYP79A1 fusion construct.  The artificially increased 
size of the linker resulted in a seemingly small increase in enzyme activity (Fig. 4B). 
Finally, particularly because the CYP needs to functionally interact with its reductase 
partner, we tested if the GFP fusion had a negative impact on the proper interactions, 
but only observed minor improvements in the activity when GFP was removed (Fig. 
S6). 
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4.4 Discussion 
The multitude of available genetic tools, growth media, and genotypes for the model 
organism E. coli is a blessing, but can also be a curse. Optimization of the physical 
parameters for heterologous gene expression is a multifactorial problem, and the 
details - from transcription to translation and post-translational processing - can be 
endlessly tinkered with. To this end, a fast reliable and inexpensive assay to optimize 
expression conditions in a high-throughput fashion is of great importance, especially 
for the design of cell factories that are based on expression of multiple challenging 
enzymes like CYPs. Membrane bound CYPs are involved in nearly all plant pathways 
leading to the formation of high value compounds. GFP has been demonstrated to be 
a useful reporter of proper expression and protein folding for soluble proteins and 
membrane proteins alike (Drew et al., 2006; 2005; 2001; Lee et al., 2014; Waldo et 
al., 1999). 
Here, we have explored the use of GFP fusions to report on the functional production 
of a commercially attractive group of single spanning membrane proteins, the multi-
gene encoded cytochrome P450 enzyme family (Morant et al., 2003). We discovered 
that the two expression strains KRX and Rosetta2(DE3) pLysS consistently 
outperforms the other tested expression strains with respect to the amount of 
functionally active P450 enzyme produced under short term induction conditions. 
KRX is a K strain and Rosetta2 is a B strain, suggesting that there is no obvious 
restriction in the use of K vs. B strains for CYP expression. The Rosetta2 strain 
provides additional copies of tRNAs that are present in low concentration in E. coli 
strains, whereas KRX does not, suggesting that this complementation is not the major 
causative effect on CYP expression in Rosetta2. Rather, a likely similarity between 
the two strains is the carefully balanced expression of the T7 RNA polymerase – in 
KRX by controlling expression directly from the Prha promoter and in Rosetta2 
indirectly by expression of lysS from the pRARE plasmid. Several of the other strains 
express lysS from the pLysS plasmid, but these do not perform as well, and we 
speculate that the difference in lysS carrying plasmid may change the production of 
lysozyme in a way that affects CYP expression. In line with this, upon removal of lysS 
from pLysS, we obtained similar expression levels in Rosetta and BL21 with all six 
P450s (data not shown). Our comparison of growth media suggests that there is no 
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“magic” medium for CYP expression, but that the minimal medium M9 without 
additional supplements is suboptimal. 
Another finding is that expression levels can be normalized to high levels using small 
peptides such as the 28-tag or membrane-spanning domains like SohB. Similar effects 
have been observed before with tags such as polyhistidine, the maltose binding 
protein (MBP) and the small ubiquitin related modifier (SUMO, for a recent review 
see (Costa et al., 2014)). The frequently observed positive effect of adding sequences 
to the 5´-end is possibly due to an incompability between the native plant 5´sequences 
with high-level expression, as previously reported for membrane protein encoding 
genes like araH and narK (Nørholm et al., 2013). An alternative solution that 
previously has proven successful is to introduce synonymous changes in the first 
couple of codons downstream from the start codon. Indeed, we have successfully 
expressed the native CYP79A1 and CYP71E1 genes by introducing a few codon 
changes in the pET expression system (data not shown). We hypothesized that the 
inherent membrane targeting of e.g. SohB would have a positive impact of expression 
and activity of an ER-derived protein targeted to the E. coli inner membrane, but 
found no significant enhancement in activity when comparing SohB with e.g. 28-
tagged CYPs. However, we also did not observe any major changes in activity 
(Fig.4b) or membrane localization of CYP79A1 even when completely removing all 
N-terminal (predicted) transmembrane segments (data not shown). Membrane 
association in the absence of N-terminal hydrophobic sequence has been observed 
before (Doray et al., 2001), suggesting that some CYPs are sufficiently hydrophobic 
to localize to the membrane in the absence of an N-terminal localization signal 
(Jensen et al., 2011).  This is also supported by molecular dynamics studies 
suggesting interactions between helices located far downstream from the N-terminus 
and biological membranes (Denisov et al., 2012). The identification of SohB as a 
generic tool to enhance expression, while being native to the E. coli membrane 
insertional machinery, may become useful when engineering higher order membrane 
assemblies such as the suggested multi-CYP metabolons (Laursen et al., 2015; 
Moller, 2010). Also, even though the lepB fusions expressed to a lower level than 
those based on e.g. SohB, the chimeric proteins were active and may become useful 
because they maintain the native plant membrane anchor and (presumably) topology. 
This is particularly relevant because our results clearly demonstrate that care should 
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be taken when truncating CYPs, as exemplified with the inactive P69-truncated 
CYP79A1. 
4.5 Conclusion 
  The presented work demonstrates the usefulness of the GFP-reporter approach 
for de-bugging and maximizing expression of a group of related enzymes, and 
suggests that there are no inherent limitations in using different standard E. coli 
strains and expression conditions for exploiting CYPs for biotechnological 
applications. Further, the peptides and membrane domains used in this study add new 
biobricks to a toolbox for engineering pathways of higher complexity such as the 
taxol biosynthetic pathway consisting of eight steps catalyzed by CYPs (Chau et al., 
2004). 
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4.7 Supplementary figures 
 
 
Fig. S1 Mining of a library of membrane encoding genes. (A) Production levels of 520 
different membrane proteins fused to GFP, based on whole cell fluorescence data previously 
published {Daley:2005jg}. SohB and YafU, selected based on their high expression levels, 
small size and topology, are highlighted in red color. (B) Production levels of 183 different 
membrane proteins fused to alkaline phosphate (PhoA), based on enzyme activity data 
previously published {Daley:2005jg}. LepB, selected based on the high expression level, 
small size and topology, is highlighted in red color. 
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Fig. S2 Effect of different N-terminal peptides and small bacterial membrane anchors on the 
expression of six different CYPs. (A) Six CYPs expressed in KRX with different N-terminal 
modifications: (from left) native sequence as reference, 28-tag fused to native CYP sequence, 
Barnes–like MALLAVF peptide fused to native CYP sequence, SohB membrane domain 
fused to a truncated CYP sequence, YafU membrane domain fused to a truncated CYP 
sequence and the LepB membrane domain fused to a native sequence. Cell cultures were 
induced for 3 h before measuring fluorescence in a multiplate reader. (B) A parallel 
experiment performed in the Rosetta2(DE3)pLysS strain. 
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Fig. S3 Expression of differently truncated variants of CYP79A1-TEV-GFP-his8 with 
different N-terminal modifications. (A) 3 h induction and (B) 22 h induction of expression of 
native CYP79A1, CYP79A1Δ1-35, 28-tag and SohB fused to CYP79A1, CYP79A1Δ1-69, 
CYP79A1Δ1-59, CYP79A1Δ1-43, CYP79A1Δ1-35 or CYP79A1 with an artificially extended 
linker region CYP79A1Δ1-35+. Constructs were expressed in KRX and cell lysates analyzed 
by in-gel fluorescence. Quantification of full-length CYP79A1-TEV-GFP-his8 vs cleaved 
GFP was performed using the Image J software. 
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Fig. S4 High performance liquid chromatography chromatograms of i) chemical oxime 
standard low conc. (0.1 µg/mL), ii) chemical oxime standard high conc. (10 µg/mL), iii) 
sample low product conc., iv) sample high product conc. and v) blank illustrated in (A) with 
fixed signal intensity and (B) with independent signal intensities. 
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Fig. S5 Co-expression for 22 h of variants of CYP79A1-TEV-GFP-his8 with the reductase 
CPR2b. Constructs were expressed in KRX and cell lysates analyzed (A) in vitro for 
conversion of L-Tyrosine to (E)-p-hydroxyphenylacetaldoxime by HPLC and (B) by whole-
cell fluorescence. Empty vector control and 28-tag:native CYP79A1 expressed without CPR 
were included as references. Error bars indicate standard error of the mean (n=3). 
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Fig. S6 Effect of the GFP moiety in the activity of different CYP79A1 variants. (A) 
Differently engineered versions of CYP79A1 with (green bars) or without (grey bars) fusions 
to GFP were co-produced with the compatible reductase electron donor CPR2b in the KRX 
strain and conversion of L-Tyrosine to (E)-p-hydroxyphenylacetaldoxime assayed by LC-MS. 
Cells were induced for 22 h, before oxime was extracted from the culture. Empty vector 
control and 28-tag:native CYP79A1 expressed without CPR were included as references. 
Error bars indicate standard error of the mean (n=3). 
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Supplementary tables  
 
Constructs Fwd oligonucleotide (5´-
3´) 
Rev oligonucleotide 
(5´-3´) 
Template DNA 
All pET28a(+)-based plasmids 
in this work had an AsiSI site 
removed like this 
ATCGCGUATTTCGTCT
CGCTC 
ACGCGAUCACTGTTAA
AAGGACAATTACAAA
CAGGAATC 
See below 
pET28a(+)-28tag-AsiSIcas-
tev-gfp-his8 
ATCGCAAGCUTGCGAT
CGCTGCTGAGGGGGTT
ATATCTCCTTCTTGGA
TCCAG 
 
AGCTTGCGAUCGCCAG
CTGAGGGAGAAAACC
TGTACTTCCAGGGTC 
pET28a(+)-28tag tev-gfp-his8 
(Nørholm et al., 2013) 
pET28a(+)-MALLLLAVF-
AsiSIcas-tev-gfp-his8 
ATCGCAAGCUTGCGAT
CGCTGCTGAGGGAAA
AACTGCTAATAACAG
AGCCATATCATCCTCG
AGTCTCCTTCTTAAAG 
AGCTTGCGAUCGCCAG
CTGAGGGAGAAAACC
TGTACTTCCAGGGTC 
pET28a(+)-28tag-AsiSIcas-tev-
gfp-his8 
(this work) 
pET28a(+)-sohB-AsiSIcas-tev-
gfp-his8 
ATCGCAAGCUTGCGAT
CGCTGCTGAGGGGCTG
AGATTGTTGACCCGTA
AC 
AGCTTGCGAUCGCCAG
CTGAGGGAGAAAACC
TGTACTTCCAGGGTC 
pET28a(+)-sohB- -tev-gfp-his8 
(Daley et al., 2005) 
pET28a(+)-yafU-AsiSIcas-tev-
gfp-his8 
ATCGCAAGCUTGCGAT
CGCTGCTGAGGGGCTG
AGATTGTTGACCCGTA
AC 
AGCTTGCGAUCGCCAG
CTGAGGGAGAAAACC
TGTACTTCCAGGGTC 
pET28a(+)-yafU-tev-gfp-his8 
(Daley et al., 2005) 
pET28a(+)-tev-gfp-his8 ATCCTCGAGUCTCCTT
CTTAAAG 
ACCTGGAUCCGAAAA
CCTGTACTTC 
pET28a(+)-28tag-AsiSIcas-tev-
gfp-his8 
(this work) 
pET28a(+)-strep-HRV3C-
CPR2b-tev 
ACCAGTGCUTCATTGA
CCCTGGAAGTACAGGT 
AGCACTGGUCTAGCAT
AACCCCTTGGGGCCTC 
pET28a(+)-strep-HRV3C-
CPR2b-tev-gfp-his8 
 
Table S1 DNA constructs made by single fragment PCR and uracil excision 
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Oligonucleotide name 
and use 
Oligonucleotide sequence (5´-3´) 
 
For cloning into AsiSI 
cassette 
 
CYP720B4_fwd GCAGCGAUGGCGCCCATGGCAGACCAAATAT 
CYP79A1 _fwd GCAGCGAUGGCGACAATGGAGGTAGAGGCCG 
CYP79B2 _fwd GCAGCGAUGAACACTTTTACCTCAAACTCTT 
CYP79F1 _fwd GCAGCGAUGATGAGCTTTACCACATCATTAC 
CYP71E1_fwd GCAGCGAUGGCCACCACCGCCACCCCGCAGC 
CYP720B4_rev GCTGGCGAUCCTTCATTCTCTACTCTACCATGA 
CYP79A1 _ rev GCTGGCGAUCCGATGGAGATGGACGGGTAGAGG 
CYP79B2 _ rev GCTGGCGAUCCCTTCACCGTCGGGTAGAGATGC 
CYP79F1 _ rev GCTGGCGAUCCTCTCTTCTTCTTTTTTTTCTTA 
CYP71E1_ rev GCTGGCGAUCCGGCGGCGCGGCGGTTCTTGTAT 
For cloning truncated 
CYPs into AsiSI cassette 
 
tCYP720B4_fwd GCAGCGAUGCCTGGGTCGACTGGATGGCCGC 
t1CYP79A1 _fwd GCAGCGAUGCCACGCAAAAGCACCACCAAGT 
t2CYP79A1 _fwd GCAGCGAUGCCGGCCGGCGTTGGCAACCCGC 
t3CYP79A1 _fwd GCAGCGAUGTACCTGGCCCGAGCCCTGAGGC 
t4CYP79A1 _fwd GCAGCGAUGTACCTGGCCCGAGCCCTGAGGCGGCCATACCTGGCCCGAGCCCTGAGG 
tCYP79B2_fwd GCAGCGAUGCCGGGTCCCACAGGATGGCCGA 
tCYP79F1 _fwd GCAGCGAUGCCTGGCCCACCAGGATGGCCCA 
tCYP71E1_fwd GCAGCGAUGCCGGGCCCTGCGCAGCTGCCGA 
 
For cloning into PCR 
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amplified pET28-variants 
nCYP720B4_fwd ACTCGAGGAUGGCGGCGCCCATGGCAGACCAAATAT 
nCYP79A1 _fwd ACTCGAGGAUGGCGGCGACAATGGAGGTAGAGGCCG 
nCYP79B2 _fwd ACTCGAGGAUGGCGAACACTTTTACCTCAAACTCTT 
nCYP79F1 _fwd ACTCGAGGAUGGCGATGAGCTTTACCACATCATTAC 
nCYP71E1_fwd ACTCGAGGAUGGCGGCCACCACCGCCACCCCGCAGC 
nCYP720B4_rev ATCCAGGUACTTCATTCTCTACTCTACCATGA 
nCYP79A1 _rev ATCCAGGUACGATGGAGATGGACGGGTAGAGG 
nCYP79B2 _rev ATCCAGGUACCTTCACCGTCGGGTAGAGATGC 
nCYP79F1 _rev ATCCAGGUACTCTCTTCTTCTTTTTTTTCTTA 
nCYP71E1_rev ATCCAGGUACGGCGGCGCGGCGGTTCTTGTAT 
strepCPR2b_fwd ACTCGAGGAUGGCGGCAAGCTGGAGCCACCCGCAGT 
CPR2b_rev ATCCAGGUACCCAGACATCACGCAGATAGCGG 
 
Table S2 Gene specific oligonucleotides used in this work 
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Chapter 5 Concluding remarks 
Concluding remarks 
The work presented in this thesis will have immediate and long-term impact on the 
way cell factories are being developed. The aim of this thesis has been to improve the 
premises for cell factory development by optimizing the cloning strategies, strain 
choice and development, as well as construct design for optimal expression of genes. 
The relevance of the conducted research to the field of biotechnology is covered, as 
well as necessary scientific background and history. The work of Chapter 2-4 describe 
our efforts to bring premises for cell factories to a new level. In Chapter 2, important 
effects of tRNA overexpression are revealed. The results offer a new perspective on a 
very popular expression system, and it is our ambition that the publication of this will 
influence how researchers consider their choice of expression system. This expanded 
understanding of side-effects explains the random success that we and others have 
experienced when applying this expression system. We can speculate that careful re-
design of the pRARE plasmid might overcome some of the challenges, but more 
research is required to support this  
In Chapter 3, a cloning strategy is described, which is designed to overcome the 
paradox of loss of flexibility due to standardization. We demonstrate that standardized 
genes can perform as well as the native versions, and the flexibility offered by this 
cloning strategy enables optimization of design-build-test cycles to achieve high titers 
of the desired compound in a cheaper and more rapid manner. Finally, Chapter 4 
covers the development of a bacterial platform for the expression of the notoriously 
difficult cytochrome P450 monooxygenases. The platform supports engineering of 
complex pathways in E. coli, and the simple screening method can relieve the heavy 
workload of compound analysis for the initial steps of cell factory development. 
 I have conducted my research in Morten H. H. Nørholms group, Membrane 
Synthetic Biology, and their continued work with the subjects covered in this thesis, 
will help pave the way for even easier cloning, better premises for strain choice and 
optimized heterologous gene expression.  
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